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Abstract
The purpose of this study was to examine the levels of pre-treatment opioid use as a predictor of success in a
multidisciplinary pain center. Much of the research on chronic pain has demonstrated that multidisciplinary
pain rehabilitation programs are beneficial and cost-effective for the reduction of pain and improvement of
functional outcomes (Gatchel & Turk, 1999). However, the use of opioid medication to treat chronic pain is
often a first and common intervention; although, its long-term effectiveness to manage pain remains
controversial (Grady, Berkowitz, & Katz, 2011; Portenoy, 1996; Turk, 1996). Over the course of the last 5-10
years, a few studies have emerged examining if patients using opioids at the start of a multidisciplinary pain
program achieve poorer outcomes in comparison to those who are not using opioids. Results have been
variable across studies and specific measures. The majority of the studies examined opioid use as a
dichotomous variable, use or no use, and all but one study mandated opioid withdrawal during treatment. The
current study examined opioid use as a dichotomous use or no use variable but also divided patients into five
subgroups in order to examine varying dosage levels on treatment outcome. Furthermore, the current study
examined the effects of continued opioid use on outcomes across domains of functioning.
The findings of this study demonstrated that participants who entered multidisciplinary chronic pain
treatment on lower levels of opioids demonstrated greater improvement in depression compared to patients
on higher levels of pre-treatment opioids. However, across all other measures, patients who reported pre-
treatment opioid use showed similar benefits from multidisciplinary pain treatment compared to patients who
reported no pre-treatment opioid use. Pre-treatment opioid use was found to be a successful predictor of post-
treatment BDI, PASS, and PSEQ scores and those patients who decreased their opioid use during treatment
demonstrated significantly greater improvement on measures of anxiety and self-efficacy compared to those
who maintained their dosage. Additionally, it is important to note that opioid users did not report decreased
pain levels or improved functioning at the start or end of treatment, which would have been expected for
patients using opioids to control pain. Future recommendations include replicating the study within a larger
and more diverse population, randomly assigning patients to opioid use conditions, and implementing
objective measurements of current opioid use at the beginning of treatment and throughout the program.
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Abstract 
 The purpose of this study was to examine the levels of pre-treatment opioid use as a 
predictor of success in a multidisciplinary pain center. Much of the research on chronic pain has 
demonstrated that multidisciplinary pain rehabilitation programs are beneficial and cost-effective 
for the reduction of pain and improvement of functional outcomes (Gatchel & Turk, 1999).  
However, the use of opioid medication to treat chronic pain is often a first and common 
intervention; although, its long-term effectiveness to manage pain remains controversial (Grady, 
Berkowitz, & Katz, 2011; Portenoy, 1996; Turk, 1996).  Over the course of the last 5-10 years, a 
few studies have emerged examining if patients using opioids at the start of a multidisciplinary 
pain program achieve poorer outcomes in comparison to those who are not using opioids. Results 
have been variable across studies and specific measures. The majority of the studies examined 
opioid use as a dichotomous variable, use or no use, and all but one study mandated opioid 
withdrawal during treatment. The current study examined opioid use as a dichotomous use or no 
use variable but also divided patients into five subgroups in order to examine varying dosage 
levels on treatment outcome. Furthermore, the current study examined the effects of continued 
opioid use on outcomes across domains of functioning. 
 The findings of this study demonstrated that participants who entered multidisciplinary 
chronic pain treatment on lower levels of opioids demonstrated greater improvement in 
depression compared to patients on higher levels of pre-treatment opioids. However, across all 
other measures, patients who reported pre-treatment opioid use showed similar benefits from 
multidisciplinary pain treatment compared to patients who reported no pre-treatment opioid use. 
Pre-treatment opioid use was found to be a successful predictor of post-treatment BDI, PASS, 
and PSEQ scores and those patients who decreased their opioid use during treatment 
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demonstrated significantly greater improvement on measures of anxiety and self-efficacy 
compared to those who maintained their dosage.  Additionally, it is important to note that opioid 
users did not report decreased pain levels or improved functioning at the start or end of 
treatment, which would have been expected for patients using opioids to control pain. Future 
recommendations include replicating the study within a larger and more diverse population, 
randomly assigning patients to opioid use conditions, and implementing objective measurements 
of current opioid use at the beginning of treatment and throughout the program. 
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Introduction 
Statement of Problem 
 Chronic pain is a pervasive and debilitating disorder that affects an estimated 50 million 
Americans. Chronic nonmalignant pain is defined as persistent or recurrent acute pain, the 
duration of which exceeds 3 months or is beyond the expected period of healing for the original 
injury (Bonica & Loeser, 2001; McCracken & Thompson, 2009). The underlying cause of 
chronic pain is often not apparent and reports of pain severity are often disproportionate to the 
physical damage (Turk & Okifuji, 2002). Chronic pain exacts a serious socioeconomic toll in 
terms of personal suffering, interpersonal distress, and widespread financial losses, as many 
patients experience a decrease in earnings and productivity and an increase in health utilization 
costs (Bajwa & Warfield, 2008; Miotto, Compton, Ling, & Conolly, 1994; Robinson, 2007). 
Patients with chronic pain are five times more likely to utilize health-care services and over 80% 
of physician visits are pain-related (Becker, et al., 1997; Gatchel & Turk, 1996). The economic 
impact of treatment costs, lost productivity, and social security disability in patients with low 
back pain alone has been calculated at $15 billion to $60 billion annually (Frymoyer & Durett, 
1997; Manchikanti, Singh, Pampati, Smith, & Hirsch, 2008). In addition to the financial impact, 
chronic pain also impacts the lives of the patient's family and friends (Turk, 2002). Given the 
complex interaction of physiological, psychological, and sociocultural factors in chronic pain, 
effective treatment is often challenging (Flor, Birbaumer, & Turk, 1990; Jensen, Chodroff, & 
Dworkin, 2007). 
 Although the current available treatments do not completely eliminate pain for the 
majority of patients, multidisciplinary pain rehabilitation programs are beneficial and cost-
effective for the reduction of pain and improvement of functional outcomes (Gatchel & Turk, 
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1999). The focus of many multidisciplinary clinics is to help patients learn effective pain 
management skills in order to increase functionality through a variety of interventions. However, 
one of the common interventions, the use of opioid medications, remains controversial. Opioid 
medications are often used for the treatment of acute and malignant pain (Portenoy, 1996). 
Although, given the long-term nature of chronic pain, the continuous use of opioids to manage 
the pain raises concerns about potential abuse and addiction, as well as their overall long-term 
effectiveness (Portenoy, 1996; Turk, 1996). In addition, researchers have shown chronic use of 
opioid medication may increase pain sensitivity (Angst & Clark, 2006; Covington, 2000) and 
decrease an individual's ability to modulate pain (Brodner & Taub, 1978; Finlayson, Maruta & 
Morse, 1986; Terman & Loeser, 1992).  
 Over the course of the last 5-10 years, a few studies have emerged examining if patients 
using opioids at the start of a multidisciplinary pain program achieve poorer outcomes in 
comparison to those who are not using opioids. Results were variable across studies and specific 
measures. The majority of the studies examined opioid use as a dichotomous variable, use or no 
use, and all but one study mandated opioid withdrawal during treatment. The purpose of this 
study was to examine the levels of pre-treatment opioid use as a predictor of success in a 
multidisciplinary pain center that does not mandate opioid withdrawal. 
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Review of Literature  
Theories of Pain  
 Pain is defined by the International Association for the Study of Pain (2009) as an 
unpleasant sensory and emotional experience associated with actual or potential tissue damage or 
described in terms of such damage. Pain is generally described as either malignant or 
nonmalignant in origin and classified as acute or chronic. Cancer pain is considered a distinct 
pain and is associated with the progression, treatment, and comorbid conditions of the disease 
(Kurita & de Mattos Pimenta, 2008; Melzack, 1993).  
 Acute pain generally results from disease, inflammation, or tissue injury and is usually 
associated with a noxious event with severity being proportionate to the degree of tissue damage. 
Acute pain is an adaptive function that sends a warning signal about harm or danger in the 
environment (Woolf, 2004). Acute pain is finite, as it is typically able to be diagnosed and 
effectively treated (Geisser, Robinson, & Riley, 1999; Melzack, 1993).  
 Although the majority of individuals suffering from acute pain recover, there remain 
those who experience continuing or chronic pain (Geisser, Robinson, & Riley, 1999; Melzack, 
1993). Chronic nonmalignant pain, by definition, is characterized as some type of persistent or 
recurrent acute pain, which exceeds 3 months or is beyond the expected period of healing for the 
original injury (Bonica & Loeser, 2001; McCracken & Thompson, 2011). In addition to duration 
of symptoms, chronic pain is often more intense than the remaining physical damage would 
predict and it may interfere with appetite, the ability to work, physical and social activity, and 
sleep (Turk & Okifuji, 2002). Gatchel and colleagues (2007) noted the pain often becomes a 
preoccupation which can exacerbate fatigue, irritability, anxiety and depression. Additionally, 
the fear of pain, fear of movement, and fear of re-injury can complicate the perception of pain.  
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 Given the complexity and the high costs of chronic pain, many theories have been 
proposed in order to explain and attempt to treat the symptoms. Currently, the biopsychosocial 
model is the standard of care, as it takes into account the complex interactions of physiological, 
biological, cognitive, affective, behavioral, and social factors. However, theories of pain have 
existed since the 17th century.  
 Biomedical theory of pain. The traditional biomedical model of pain dates back to 
ancient Greece in the 17th century. Descartes described pain according to the medical model, 
which assumed that pain resulted from a specific disease or dysfunction of biology. Therefore, 
pain should cease upon removal or repair of the biological disturbance. Based on the medical 
model, tests are used to make a diagnosis of the disease, which then informs the treatment 
intervention (Flor & Turk, 1988). This model assumes that non-biological factors have no role in 
the patient's experience of pain. The criticism of the model is its inability to account for 
discrepancies between pain report and physical pathology (Flor & Turk, 1988). In 1959, Engel 
attempted to explain this discrepancy by proposing that pain has special meaning to some 
patients, he coined the term psychogenic pain. Engel described the “pain prone patient” as 
having several characteristic features, including guilt, aggressive drives, and specific psychiatric 
disorders. While Engel's theory examined psychosocial factors, it overweighed the psychological 
factors and failed to take into account the interaction of the biological and psychosocial factors 
that affect chronic pain (Turk & Okifuji, 2002).  
 Gate control theory. The first comprehensive pain theory to integrate both physical and 
psychological factors was the “gate control theory of pain,” introduced by Melzack and Wall in 
1965. Melzack and Wall (1965) hypothesized that central nervous system mechanisms provide a 
physiological basis for psychological involvement in pain perception. The theory suggests that 
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the dorsal horns of the spinal cord act as a “pain gate,” regulating the transmission and intensity 
of nerve impulses to the central nervous system. It is suggested that psychological factors, such 
as stress, influence how wide or narrow the gate is opened, thereby regulating the level of 
perceived pain. While the gate control theory of pain has been criticized as being incomplete, it 
is one of the first theories to directly recognize the interaction between the mind and body (Turk 
& Monarch, 2002). 
 Neuromatrix theory. One of the main criticisms of the gate control theory is that it is 
incomplete, as it does not account for pain associated with paralysis or severed limbs. In order to 
address these criticisms, Melzack elaborated on his theory, proposing that the perception of pain 
is generated by a large number of interconnected neurons, a neuromatrix, which is initially 
determined by genetics and later sculpted by stimuli from the environment (Melzack, 2005; 
Mosley, 2003). The environmental stimuli include sensory information from the physical body, 
cognitive information from past experiences, and emotional information from the limbic system 
(Melzack 2005). Over the course of a life time, the neuromatrix constantly receives 
environmental stimuli and then generates nerve impulses or neurosignature patterns, which are 
involved in perceiving, reacting, and regulating pain (Melzack, 2005; Moseley, 2003). The 
neurosignature forms a continuous loop that supplies a steady stream of feedback of awareness 
and action (Melzack, 2005). The theory that pain is not produced by a single pain center in the 
brain, but rather by a widely dispersed pattern of activation, provides a framework for 
understanding the importance of a person’s genetics, experiences, emotional status, stress levels, 
and environmental factors on pain sensations. 
 Biopsychosocial model of pain. The evolution of biomedical, gate control, and 
neuromatrix theories has led to a more comprehensive and multidimensional view of pain. The 
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biopsychosocial model of pain posits that a complex interaction of physical factors, 
psychological processes, and social factors influence the severity and duration of pain symptoms 
(Turk & Okifuji, 2002). This interplay of factors may be linear or nonlinear and each component 
is influenced by and influences the other components (Turk, 1996). The biopsychosocial model 
has become a popular model in conceptualizing chronic pain (Nicassio & Smith, 1995) and is the 
framework for this study.  
 One of the fundamental concepts of the biopsychosocial model is the distinction between 
disease and illness. Disease has been defined as an objective biological event involving the 
disruption of specific body structures or organ systems caused by anatomical, pathological, or 
physiological changes (Turk & Monarch, 2002). In contrast, illness is viewed as the subjective 
experience or perception that a disease is present and focuses on the complex interaction of 
biological, psychological, and social factors (Gatchel, 2005; Turk & Monarch, 2002).  
 Turk and Okifuji (2002) stated that in the biopsychosocial model, biological factors are 
important in initiating and maintaining pain in the acute phase, as some form of physical 
pathology generates nociceptive input to the brain. Additionally, the physical injury also disrupts 
the body’s homeostatic regulation systems, which in turn produces stress as the body tries to 
restore homeostasis (Gatchel et al., 2007). Researchers have shown, as the body continues to be 
stressed, the hypothalamic-pituitary-adrenal (HPA) axis increases the production of cortisol 
(Melzack, 1999). In turn, the increased level of cortisol can cause muscle atrophy, impairment of 
tissue repair, and suppression of the immune system, which can cause more pain and continue 
the pain cycle (Gatchel et al., 2007; Melzack, 1999).  
 While biological factors may initiate the pain symptoms, it is often the psychological and 
social factors that help maintain or exacerbate the level of pain. There are a number of 
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psychological factors that impact the interpretation and appraisal of the nociceptive input, 
thereby impacting pain perception. An individual's beliefs about the meaning of symptoms, self-
efficacy, coping, and response to treatment all play a role in chronic pain and the patient's 
perception of their illness (Jensen, Romano, Turner, Good, & Wald, 1999; Stroud, Thorn, 
Jensen, & Boothby, 2000). Researchers have shown that an individual's current mood state 
modulates pain reports and tolerance for acute pain (Fernandez & Turk, 1992; Turk & Monarch, 
2002). For example, Gatchel (2005) found that depression level was associated with chronic pain 
and played a significant role in premature termination from pain rehabilitation programs (Kerns 
& Haythornthwaite, 1988). Additional research has shown that 40% – 50% of chronic pain 
patients suffer from depressive disorders (Banks & Kerns, 1996; Dersh, Gatchel, Mayer, Polatin, 
& Temple, 2006; Romano & Turner, 1985) and while several studies have found that chronic 
pain can cause depression (Atkinson, Slater, Patterson, Gant, & Garfin, 1991); other studies 
found that depression can cause chronic pain (Magni, Moreschi, Rigatti Luchini, & Merskey, 
1994). Still other studies have found depression and chronic pain exist in a mutually reinforcing 
relationship (Rudy, Kerns, & Turk, 1988). Turk and colleagues (1995) investigated possible 
mediating factors of depression and chronic pain and found that the patients’ beliefs about their 
pain and their ability to control their pain played a significant role in depression levels. 
 Anxiety, fear of pain, and harm avoidance have also been shown to increase pain 
symptoms. Asmundson and colleagues (2000) found that anxiety sensitivity played a significant 
role in predisposing and augmenting the experience of pain. Commonly reported fears from 
patients are anxiety the pain will increase, more injury will occur, physical capacity will 
diminish, employment concerns, and concerns regarding the future and family relationships 
(Gatchel, 2007). Patients often report fear and anxiety regarding activities that they anticipate 
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will increase their pain, which often leads to avoidance, inactivity, and long-term increase in pain 
(Boersma & Linton, 2006). Research has shown that fear of movement and fear of injury are 
better predictors of functional limitations than medical factors or even pain severity and duration 
of pain symptoms (Turk, Robinson, & Burwinkle, 2004). Additionally, McCracken and Gross 
(1998) found that a reduction in pain-related anxiety significantly predicted improvement in 
functioning, affective distress, pain, and pain-related interference with activity (McCracken & 
Gross, 1998).  
 Cognitive factors also a play a part in the biopsychosocial model and contribute to an 
individual experience of pain. Concerns about the future, beliefs about the meaning of pain, 
perceived control and self-efficacy, catastrophizing, fear-avoidance beliefs, and vulnerability and 
resilience have been identified as cognitive factors that significantly impact the experience of 
pain (Gatchel, 2007; Turk & Okifuji, 2002). For example, research has shown that patients who 
were educated by physicians about their treatment and believed in the rationale were more likely 
to have positive outcomes than those who did not see rationale in the treatment (Schwartz, 
DeGoode, & Shutty, 1985). 
 In a study done by Williams and Keefe (1991), pain patients who believed their pain was 
enduring and mysterious reported having less confidence in pain management and less 
confidence in their abilities to manage their own pain. Furthermore, in a study done by Keefe and 
colleagues (1989), pre-treatment patients who exhibited a high frequency of catastrophizing were 
found to have higher pain ratings, greater physical disability and depression at 6 month follow 
up, compared to patients who exhibited lower levels of catastrophizing. 
 Psychosocial variables are also associated with pain and distress. Turk and Okifuji (2002) 
conducted a literature review of studies investigating predictors of pain chronicity and long-term 
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disability. Factors such as compensation status, prevalence of pain behaviors, job dissatisfaction, 
affective reactivity, maladaptive attitudes and beliefs, inadequate social support, substance abuse, 
and psychopathology were the strongest predictors of chronic disability. The psychosocial 
factors contributed more than the physical factors in the prediction of chronicity and long-term 
disability. Social factors such as pain behaviors, physical disabilities, and nonverbal pain 
behaviors have also been associated with disability rates and post-surgical outcomes (Tillotson, 
Main, & Hollis, 1995; Schofferman, Anderson, Hines, Smith, & White, 1992). Family and 
friends also play an important role in influencing pain reports, communications, and suffering. 
Reinforcement of pain behavior, solicitousness, criticism, and marital conflict are among the 
social factors that play a role in chronic pain (Graham, 2000; Schade, Semmer, Main, Hora, & 
Boos, 1999). 
  Gatchel (1996) working from the biopsychosocial framework proposed a broad 3-stage 
model of transition from acute to chronic pain as it relates to lower back pain. Stage 1 occurs 
during the acute phase of the injury and is associated with the emotional reactions resulting from 
the perception of pain. If the pain persists past the reasonable acute period of time, individuals 
move into Stage 2, which is more associated with chronic pain. During stage 2 a wider array of 
psychological reactions occurs, including feelings of helplessness, depression, anxiety, and 
anger. Gatchel argued that the impact of Stage 2 will vary for each individual, based on their 
premorbid psychological characteristics and current socioeconomic conditions. This stage of the 
model reflects a diathesis-stress perspective, in which the stress of coping with chronic pain 
exacerbates the individual’s preexisting characteristics. Gatchel proposed that as the 
psychological problems persist, individuals move into Stage 3, which is viewed as acceptance of 
the sick role. During this stage, patients often stop performing their normal responsibilities and 
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social obligations, which may be reinforced by psychosocial factors. The complex interaction of 
the biological, psychological, and psychosocial factors acts as dual feedback mechanisms, with 
each component exacerbating the others. For example, adoption of the sick role can lead to 
physical deconditioning, which can cause chronic pain patients to stop working, subsequently 
lowering their self-esteem and increasing anxiety, and thereby increasing pain symptoms and 
adopting more of a sick role (Kidner, Mayer, & Gatchel, 2009).  
 The development of the biopsychosocial theory has resulted in a more comprehensive 
understanding and treatment of pain. Research has shown that the interactions among biological, 
psychological, and social factors determine the severity and chronicity of pain and helps to 
explain the diverse pain symptoms experienced by individuals. Additionally, the biopsychosocial 
model has allowed for the development of a more multidimensional approach to treatment. 
 
Treatment of Chronic Pain  
 Biomedical Treatment of Pain. Historically, chronic pain was been treated from a 
traditional biomedical model or a reductionist model (Portenoy et al., 2007). From this 
perspective, pain is viewed as solely a signal of injury and tissue damage. Treatment for chronic 
pain under this model commonly entails isolating the specific physical defect thought to be 
causing the pain and attempting a mechanical fix (Pincus & Morley, 2001). The biomedical 
model provided pharmacological treatment for symptom management (Portenoy et al., 2007). 
Many physicians still provide treatment using the biomedical model (Joranson, Ryan, Gilson, & 
Dahl, 2000). One hypothesis is that under the biomedical model, responsibility for treatment 
resides with the physician and the patient takes more of a passive role in treatment (Joranson, 
Ryan, Gilson, & Dahl, 2000). Unfortunately, the biomedical approach to understanding and 
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treating chronic pain does not take into account the complex interaction of psychological and 
social factors as previously discussed. 
 Biopsychosocial Treatment of Pain. As the theory of pain has evolved so has research 
and clinical treatment for chronic pain. The treatment of chronic pain has evolved to a 
multidimensional, multidisciplinary framework, often referred to as Multidisciplinary Pain 
Treatment Program (Jacobson & Mariano, 2001). In order to effectively treat chronic pain based 
on the biopsychosocial model, treatment must address the biological basis of pain, as well as the 
interaction among biological, social and psychological factors that contribute to pain, distress, 
and disability (Gatchel & Turk, 1996). Treatment interventions in multiple disciplines work 
together towards providing patients with a variety of tools to help them gain a sense of control 
over the pain and their lives (Gatchel & Turk, 1996).  
 The integration of the multiple disciplines, strategies, and interventions into a unified 
approach allows for a more comprehensive approach to patient care. The treatment teams 
typically include physicians, nurses, psychologists, vocational therapists, physical therapists, 
biofeedback therapists, occupational therapists, and others (Aronoff, 1998). Within each 
treatment discipline, the emphasis is on active involvement of the patient as they learn self-
management skills for their pain. The common components of biopsychosocial pain treatment 
include (a) medication management; (b) stress management; (c) individual, group, and family 
psychotherapy; (d) physical and occupational therapy; (e) vocational therapy (Andrasik et al., 
2007; Cano et al., 2006; Lemstra et al., 2005; Nielson et al., 2001).  
 Medication. Physicians typically provide patients with medication management, 
treatment coordination, and education (Aronoff, 1998; Loeser & Turk, 2001). Medication is one 
of the most commonly used modalities for pain management. The medications used in the 
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treatment of chronic pain include but are not limited to: antidepressants, antiepileptics, opioid 
analgesics, benzodiazepine, and barbiturates (Loeser & Turk, 2001). Antidepressants are helpful 
in patients with depressive symptoms and some antidepressants, such as Effexor and Cymbalta, 
have an additional effect on pain (Gilron et al., 2006; Martin et al., 2007; Moulin et al., 2007). 
Antiepileptics are useful in the treatment of pain that originates from disease or damage of the 
nerves. Opioids, which will be discussed in more detail later, benzodiazepines, and barbiturates, 
are used to lessen the sensation of pain but have been shown to have significant side effects, 
including opioid induced hyperalgesia (Rosenblum, Marsch, Portenoy, & Joseph, 2008).  
 Stress Management. The complex interplay of biology, psychology and social factors 
has been show to significantly increase the physiological arousal associated with chronic pain. 
Biofeedback can be used to facilitate stress management. Therapists provide education on 
relaxation techniques and monitor the patient's physiological responses while they engage in 
relaxation. Biofeedback modalities that may be included are electromyography, galvanic skin 
response, and respiration (Haythornthwaite et al., 2001). Through the use of biofeedback, 
patients are able to observe, monitor, and react to changes in their bodies as they engage in 
relaxation. Research has shown that through the use of biofeedback, patients are able to develop 
some capacity to control their bodies (Andrasik, 2003). Additionally, patients learn the 
importance of physiological arousal in pain management (Loeser et al., 1990) and are able to 
tangibly see the effects of emotion on a body's physiologic state (Andrasik et al., 2007; Astin, 
2004; Bruehl et al., 2006; Haythornthwaite et al., 2007; Nestoriuc et al., 2007; Trautmann et al., 
2006). 
Individual and Group Psychotherapy. Psychologists provide individual, group, and 
family therapy, using a variety of intervention strategies including behavioral modification and 
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cognitive-behavioral techniques (Aronoff, 1998; Loeser & Turk, 2001). Psychologists play an 
important role in educating patients on the interactions between thoughts, emotions, and 
behaviors and how these can affect their pain. Helping patients to understand that chronic pain is 
conceptualized from a biopsychosocial framework is also a task entrusted to a psychologist. The 
initial education piece is an important step in enabling the patient to take an active role in their 
pain management and helping to develop a broader set of coping skills. Additionally, 
psychologists are charged with the task of dealing with issues of depression, anxiety, and 
relationship problems that are commonly associated with chronic pain. Psychologists also assist 
other multidisciplinary team members in developing and using behavioral strategies in their 
interventions with patients (Aronoff, 1998; Loeser et al., 1990).  
Behavior modification is an important aspect of every level of care with patients. Often 
pain-related behaviors develop over time and are reinforced through interactions with family 
members and secondary gains, including financial and medication based gains (Gallagher, 2005). 
Multidisciplinary teams work together across fields to reinforce non-pain related behaviors and 
to ignore pain-related ones (Buenaver et al., 2008; Gallagher, 2005; Hoffman et al., 2007; 
Lemstra et al., 2005). Behavior modification also occurs in the context of family therapy. The 
family is the primary unit of social interaction for the patient and as such, helps to shape illness 
or wellness (Haythornthwaite et al., 2001; Turk et al., 2004). Lewandowski and colleagues 
(2007) found that the pain management program was more likely to work when the patient's 
family was involved in the treatment. Psychologists may work with the families providing 
education and insight into their roles of pain related behaviors (Nickel et al., 2008).  
 Physical and Occupational Therapy. Physical therapists provide education to patients, 
conduct musculoskeletal evaluations, and treatment for musculoskeletal dysfunction (Loeser & 
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Turk, 2001). Physical therapists work towards developing an active exercise program that 
emphasizes general conditioning, posturing, flexibility, and strengthening (Lemstra et al., 2005; 
Robinson, 2007). Common physical therapy treatments include ice and heat therapy, electrical 
stimulation, massage, cardiovascular exercise, weight and resistance training, stretching, range of 
motion, mobility, and endurance exercises (Aronoff, 1998; Loeser et al., 1990; Loeser & Turk, 
2001). Additionally, physical therapists work with psychologists to help patients learn the 
concept of pacing or breaking activities into smaller manageable tasks. 
 Occupational therapists educate patients in proper stretching, body mechanics, pacing, 
work hardening, ergonomics, and ways to accomplish other tasks of daily living given their 
physical limitations (Aronoff, 1998; Loeser & Turk, 2001). Occupational and physical therapist 
often work together in helping to modify recreational activities or initiating new activities, 
thereby increasing overall quality of life (Loeser & Turk, 2001).  
 Vocational Therapy. Vocational therapists are also involved in the multidisciplinary 
treatment of chronic pain patients (Loeser & Turk, 2001). Patients often receive an assessment of 
their interests, education, aptitude, physical capacities, learning capabilities, work experience, 
and transferable skills (Loeser & Turk, 2001). The vocational therapists will then work with 
patients to develop realistic vocational goals and provide occupational counseling. Additional 
services include, helping patients navigate the Workman’s Compensation system, providing job 
finding and interview skills, placement counseling, work hardening, and may serve as liaison 
when the patient is seeking a job (Loeser & Turk, 2001). Vocational therapists work alongside 
the psychologists, medical physicians, and physical and occupational therapists to provide 
thorough and comprehensive care for the patient. 
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 Numerous studies have shown the efficacy of a multidisciplinary treatment approach in 
the treatment of chronic pain (Hoffman et al., 2007; Hooten et al., 2007; Jensen et al., 2007; 
Stanos et al., 2006; Vowles et al., 2007). One hypothesized reason for the success of the 
multidisciplinary treatment is that it works from a biopsychosocial framework, where a 
multidisciplinary team works together to address the biological, psychological, and psychosocial 
aspects that maintain and exacerbate pain symptoms. One of the criticisms of Multidisciplinary 
Pain Treatment Program is the lack of an appropriate screening tool to help to determine who 
will most benefit from this treatment (Pereira & Smith, 2006). Retrospective research that 
examined negative predictors of treatment completion found the following were relevant 
predictors of lower treatment efficacy and less likelihood of treatment completion: a negative 
relationship with the employer; poor work satisfaction; a negative outlook about future 
employment; high levels of psychosocial distress and pre-treatment depression; financial 
disability disputes; smoking; duration of disability; pre-treatment levels of pain; and prevalence 
of opioid use (Bendix, 1998; Gatchel, 2005; Linton, 2001). 
 
Opioids 
 Opioid therapy has been a mainstay approach for the treatment of moderate to severe pain 
associated with cancer, acute pain, or other serious medical illnesses (Savage, 2002; World 
Health Organization, 1996). However, the use of opioid analgesics for the treatment of chronic 
pain has remained controversial due to concerns about side effects, long-term efficacy, functional 
outcomes, and the potential for drug misuse, abuse, addiction, and diversion (Savage, 2002).  
 Definition and Mechanism of Action. Opioids are a group of medications defined as 
having an effect on the body similar to that of morphine. An analgesic effect is produced when 
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 opioid medications bind to opioid receptors located throughout the central nervous system, with 
higher concentrations in the limbic system, thalamus, striatum, hypothalamus, midbrain, and 
spinal cord (Jaffe & Martin, 1990). Several types of opioid receptors exist (mu, kappa, and 
delta); however, activation of the mu opioid receptors is largely responsible for the analgesic 
effect of common opioid medications, such as morphine, oxycodone, and methadone 
(Rosenblum, Marsch, & Joseph, 2008). Often referred to as opioid agonists or full mu agonists, 
these opioids produce greater receptor activation when given in greater doses. Conversely, 
opioids, such as naltrexone and naloxone, occupy but do not activate receptors and are referred 
to as opioid antagonists. These opioids block the receptors, preventing other opioids from 
binding. Antagonists may also either have a low intrinsic activity at the mu receptor or are 
agonists that are characterized by a ceiling, such that increases in dose will minimally increase 
the drug’s effects only to a certain level and increases in dosage no longer produce additional 
effects (Jaffe & Martin, 1990).  
 Clinically, opioid medications are often classified as either “weak” or “strong,” based on 
the level of pain for which they are effective. Patients with moderate pain are often prescribed 
“weak” opioids, such as codeine, dihydrocodeine, and tramadol. Whereas, “strong” opioids, such 
as, morphine, methadone, oxycodone, hydrocodone, and pentazocine are reserved for severe pain 
(Bannwarth, 1999). Typically, opioid medications with shorter half-lives are not prescribed to 
patients with chronic pain due to the high dosage requirement and the higher risk of abuse due to 
the initial high felt after taking them (Bannwarth, 1999). Published treatment recommendations 
suggest physicians start at the lowest possible therapeutic dose, allowing adequate time during 
titration for tolerance to adverse effects, and then if treatment is inadequate, duplicate with a 
higher level opioid or add a second opioid at low dose (Portenoy et al., 2007). 
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 Side Effects. Opioid use is associated with several potential side effects which can 
interfere with overall functioning and with analgesic effects of the medication. Common short-
term side effects include nausea, vomiting, constipation, sedation, dizziness, and cognitive 
impairment (Bannwarth, 1999; Furlan, Sandoval, Mailia-Gagnon, & Tunks, 2006; Moore & 
McQuay, 2004). Moore and McQuay (2005) conducted a systematic review of the literature to 
include all randomized double blind trials of oral opioid use in non-cancer pain and with placebo 
or active comparison. Their review of 34 studies with 4,212 patients found that one in two 
patients experienced at least one adverse side effect and one in five discontinued usage due to 
side effects, which was significantly higher than the placebo group reported. The most common 
adverse side effects were nausea (21%), constipation (15%), dizziness (14%), and drowsiness or 
somnolence (14%).  
 Often short-term side effects are treated as they arise and commonly dissipate as 
tolerance builds (Cherny, 1996); however, long-term effects may still persist. In a study of the 
long-term adverse side effects of opioid use, researchers found that after 13 months of 
transdermal fentanyl or sustained-release morphine use, 34% of patients (N= 680) withdrew due 
to adverse effects (Allan, Richarz, Simpson, & Slappendel, 2005). Other long-term studies have 
found similar discontinue rates; however, it is unknown from those studies if other factors (i.e., 
efficacy, physician, finance) contributed to the discontinuation (Kalso Edwards, Moore, & 
McQuay, 2004; Martell, 2007). There is also limited data that suggest that long-term opioid use 
could increase the risk of bone fractures. A review of six studies found opioid use was associated 
with a 40% increase in relative risk for any fracture compared to non-use (Takkouche, Montes-
Martinez, Gill, & Etminam, 2007). The study also found risks associated with opioids were 
similar to risks associated with benzodiazepines, antidepressants, and non-barbiturate 
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antiepileptic drugs. In another study, Vestergaard and colleagues (2006) found that morphine, 
fentanyl, methadone, oxycodone, tramadol, and codeine were all associated with increased 
fracture risk, with higher dosages being associated with higher risk. However, bone density, 
cognitive impairment, and other possible confounding variables were not able to be accounted 
for in this study studies. 
 The risk of cognitive impairment as a side effect of opioid use remains controversial and 
the research is often contradictory. Chapman and colleagues (2002) posit that since many opioid 
receptors are located in areas of the brain involved in learning, memory, and attention, cognitive 
dysfunction is a serious concern. Another study found that long-term opioid therapy produces a 
slight, albeit non-significant, impairment of psychomotor performance in patients with chronic 
pain (Larsen et al., 1999). Conversely, other studies have found sedation and cognitive deficits 
are only early side effects which diminish with stable dosing (Haythornthwaite, Menefe, 
Heinberg, & Clark, 1998; Lorenz, Beck, & Bromm, 1997). Zacny et al. (1994) found that some 
aspects of psychomotor performance such as reaction time were impaired by morphine; however, 
eye-hand coordination was not. The effects of morphine appeared to be dose-related, with effects 
peaking soon after the injection and dissipating gradually. Other researchers have suggested that 
pain itself is the cause of cognitive impairment, while others hypothesize it is the concurrent use 
of sedative medications which effects cognitive functioning (Lorenz, Beck, & Bromm, 1997; 
Savage, 1999). 
 Chronic opioid therapy has also been associated with a phenomenon referred to as 
opioid-induced hyperalgesia or OIH (Compton, 1994; Savage, 1999; Schofferman, 1993). OIH is 
the result of paradoxical opioid sensitization of the central and peripheral nervous system to pain. 
Patients with OIH are particularly sensitive to cold stimuli and may also have allodynia, whereby 
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a non-painful stimulation of the skin results in pain (Chu, Angst, & Clark, 2008; Schofferman, 
1993). Although, the precise mechanism of OIH had not clearly been identified, a number of 
theories have been proposed. One hypothesis is that opioids increase the transmission of 
nociceptive signals by inducing the up regulation of excitatory N-methyl-D-aspartate (NMDA) 
receptors in the central nervous system (Mao et al., 1994; Mayer et al., 1999). Another proposed 
theory is that chronic opioid use may lead to an increased production of the anti-opioid 
neuropeptides (Gardell et al., 2003; Vanderah et al., 2000). Research has shown that opioids 
binding to receptors in the brainstem can result in increased release of a pro-nociceptive peptide, 
cholecystokinin (CCK), in the medulla, which can increase pain sensitivity (Chu, Angst, & 
Clark, 2008; Colvin & Fallon, 2010). 
 Clinical studies have reported that rapid opioid dose escalation and a preferred 
administration route can produce hyperalgesia and allodynia (Chu, Clark, & Angst, 2006; 
Sjogren, Jensen, & Jensen, 1994; Sjogren et al., 1993). Evidence from a number of studies 
suggests that the use of opioids can result in tolerance and/or hyperalgesia. In a group of studies 
evaluating patients undergoing surgery, patients who endorsed preoperative use of opioids were 
predisposed to higher levels of postoperative pain and requested higher levels of postoperative 
opioids (Arendt-Nielsen, 2006; Chu et al., 2006; Rapp, Ready, & Nessly, 1995). Similarly, the 
use of high doses of opioids during surgery has also been linked to higher postoperative pain and 
opioid requirements to manage the pain (Chu et al., 2006; Guignard et al., 2000). Finally, several 
volunteer studies have shown that the short-term infusion of remifentanil aggravates preexisting 
hyperalgesia (Chu et al., 2006; Hood, Curry, & Eisenach, 2003). Overall, research has started to 
show that opioids administered to alleviate chronic pain, instead, may increase pain sensitivity 
and aggravate pre-existing pain (Angst & Clark, 2006).  
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 Opioid Abuse. In the current literature regarding prescription opioid misuse and abuse 
there is a lack of a standardized definition for many terms and the way in which they are used 
(Compton & Volkow, 2006). The American Academy of Pain Medicine, American Pain Society 
and American Society of Addiction Medicine have described opioid addiction as a chronic, 
neurobiological disease, characterized by impaired control over drug use, compulsive use, and 
continued use despite harm, or cravings (Savage, Covington, Heit, Hunt, Joranson, & Schnoll, 
2001). Portenoy (2004) defined opioid addiction in the context of chronic pain patients as a 
psychological and behavioral disorder characterized by evidence of psychological dependence, 
and compulsive drug use or other aberrant drug-related behaviors. 
 The Diagnostic and Statistical Manual, Fourth Edition Text Revision (DSM-IV-TR) 
defines substance abuse as a clinically maladaptive pattern of substance-related behaviors that 
include failure to fulfill major role obligations, recurrent involvement in physically hazardous 
situations and illegal activities and persistent social and interpersonal problems. For substance 
dependence, the definition of substance abuse is extended by the addition of the presence of 
tolerance, withdrawal, and compulsive drug taking behaviors. 
 Given the stigmatization that may accompany a diagnoses of opioid abuse, the National 
Institute on Drug Abuse (NIDA) released the “Research Report Series-Prescription Drugs: 
Abuse and Addiction” (2008) in which prescription drug misuse was defined as “taking a 
medication in a manner other than that prescribed or for a different condition than that for which 
the medication is prescribed” (p. 11) and prescription drug abuse as “the intentional misuse of a 
medication outside of the normally accepted standards of its use.” (p. 11). The American Society 
of Addiction Medicine, the American Academy of Pain Medicine, and the American Pain 
Society also developed a definition, whereby misuse is defined as “Use of a medication (for a 
medical purpose) other than as directed or indicated, whether willful or unintentional, and 
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whether harm results or not” and for prescription opioid abuse: “Any use of an illegal drug, and 
the intentional self-administration of a medication for a non-medical purpose such as altering 
one’s state of consciousness, for example, getting high” (Katz et al., 2007, p. 650).  
 Tolerance for medication is typically identified when increased doses are necessary to 
sustain the initial effects of the drug (Bannwarth, 1999; McQuay, 1999; Savage, 1999). Although 
tolerance can be present in addiction, is not necessarily indicative of addiction. Several studies 
have posited that opioid tolerance is pharmacologically based, that there is a change in the 
metabolism, distribution, or degradation of the drug, as well as, neuroadaptation at the receptor 
level (Compton, 1994; Savage, 1999). Other researchers have suggested that disease progression 
itself is directly indicative of the need for increased medication dosage. 
 Physiological dependency has been defined as the physiological adaptation to a 
substance, where the discontinuation or decrease in dosage results in withdrawal symptoms 
(Savage, 1999). Physical dependency is expected to occur in nearly all patients who use opioids 
for more than a few days, or with frequent episodic use, depending on dosage intervals and levels 
(Savage, 1999). Similar to tolerance, physical dependency may be present in addiction, but not 
necessary or sufficient for diagnosis. 
 There has been much debate about the definition of addiction as it relates to opioid use, 
specifically with pain patients. In 2001, the American Society of Addiction Medicine, American 
Academy of Pain Medicine, and American Pain Society developed a consensus definition of 
addiction, based primarily on the biopsychosocial model (Savage et al., 2001). The committee 
defined addiction, as applied to pain patients taking opioid medications, as a chronic, 
neurobiological disease, with genetic, psychosocial, and environmental factors influencing its 
development and manifestations. It is characterized by impaired control over drug use, 
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compulsive use, continued use despite harm, and/or cravings (Liaison Committee on Pain and 
Addiction, 2001). 
 Several risk factors for substance addiction have been identified, including demographic, 
social, genetic, psychiatric, and personality factors (Portenoy, 1996; Robinson et al., 2001; 
Strain, 2002). According to the 1998 National Institutes of Health Consensus Conference on 
Opiate Addiction, biological factors, such as heredity may play a part in drug abuse. Two genetic 
pathways that have been shown to increase the risk of drug abuse are having a biological parent 
who abused drugs and having a biological parent who has a diagnosis of antisocial personality 
(Robinson et al., 2001). Psychosocial features such as lower socioeconomic status, children from 
divorced and single-parent homes and children who exhibit behavioral problems have also been 
associated with higher risk of drug abuse (Robinson et al., 2001). Psychological factors linked to 
higher risk of opioid abuse or dependence include, depression, alcohol abuse, antisocial 
personality disorder, posttraumatic stress disorder and conduct disorders, These diagnoses appear 
more often in opioid-dependent individuals than in non-opioid-dependent individuals. Given the 
complex nature of opioid abuse, researchers have recommended the use of a biopsychosocial 
assessment in determining a patient's risk factors for abuse.  
 Chronic Pain and Opioid Use. Despite concerns about the long-term safety of opioid 
use, overall prescriptions for opioids have increased 127% from 1997 to 2006 (Manchikanti & 
Singh, 2008). In addition to the increase of opioid use, research has shown that the type of 
opioids prescribed has also changed. According to Manchikanti and Singh (2008), in 1997 the 
most commonly used opioid was codeine, followed by hydrocodone and oxycodone. However, 
in 2006, the most commonly used opioid was oxycodone, followed by hydrocodone and 
morphine.  
28 
 
 Given the significant increase in opioid medication use for the treatment of pain, multiple 
studies have been conducted to study the efficacy of opioid therapy. These studies support the 
efficacy of opioid use in cancer patients, as it has shown to relieve pain in 70-90% of cases, 
increase patient functioning and improve quality of life (Jorgensen, Mortensen, Jensen, & 
Eriksen, 1990). However, research regarding the opioid therapy for the treatment of chronic 
nonmalignant pain remains inconclusive.  
 A number of early studies support the efficacy of opioid therapy for the treatment of 
chronic pain and negate the risk and negative side effects (Jamison, Anderson, Petters-
Asdourian, & Ferrante, 1994; Urban, France, Steinberger, Scott, & Maltbie, 1986; Green & 
Coyle, 1989). In a 1994 study, Jamison and colleagues found that 83% (N= 112) of patients 
reported moderate or better pain relief on opioid maintenance, 82% reported minimal or no side 
effects, and 60% reported no or minimal need to increase dosage over time. In a smaller study 
examining 16 patients who received opioid medication while enrolled in an inpatient 
interdisciplinary pain treatment program, 13 of the 16 patients reported 75-99% relief from pain 
and the remaining 3 patients reported 50-74% relief. Additionally, 12 of these patients showed 
increases in their activity level or returned to work. However, upon follow-up several months 
later, 63% of patients reported a decrease in the effectiveness of their opioid medications 
(France, Urban, & Keefe, 1984). Conversely, Tennant and colleagues (1988) examined 52 
chronic pain patients who were on varying doses of opioids (10- 240 mg of methadone) and 
found that 88% of patients reported adequate pain relief and 12% reported partial pain relief, 
without dosage elevations. However, 17% of patients in the study demonstrated abuse behaviors 
and all patients experienced significant side effects including constipation and edema. Although 
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early research on the efficacy and safety of long-term opioid treatment provided mixed results, 
early trials were uncontrolled studies with small populations. 
 Over the past two decades, researchers have begun to conduct controlled studies to 
further investigate the efficacy of opioids in treating chronic pain (Arkinstall et al., 1995; Watson 
& Babul, 1998; Moulin et al., 1996). In randomized controlled study, Watson and Babul (1998) 
found controlled-release oxycodone to be superior to placebo in reducing pain intensity among 
elderly chronic pain patients. Similarly, Moulin and colleagues (1996) reported oral morphine 
significantly decreased pain relative to placebo among chronic pain patients; however, 
improvements in psychological functioning and quality of life were not found. 
 Rowbotham and colleagues (1996) conducted a randomized study to examine varying 
dosage of opioid in the treatment of chronic pain. Patients (N=81) were identified as a low-
strength group (average 2.7 mg of levorphanol) or a high-strength (average 8.9 mg of 
levorphanol). Overall, results indicated that higher doses of opioids lead to significantly greater 
reduction in pain intensity; however, doses higher than 8.9 mg produced more side effects 
without significant added benefit. 
 Conversely, there have also been numerous reviews that have critically evaluated the 
effectiveness of opioid therapy in chronic pain (Ballantyne, 2007; Cepeda, Camargo, Zea, 
Valencia, 2007; Chou, Clark, & Helfland, 2003; Furlan et al., 2006; Trescot et al., 2006). In a 
meta-analysis of opioid use in patients with chronic low back pain, Martell and colleagues 
(2007) found that opioids did not provide effective pain relief and did not improve the overall 
functioning of patients with lower back pain. Kalso and colleagues (2004) conducted a critical 
analysis and concluded that the mean decrease in pain intensity in most studies was 30% among 
opioid users compared to the 44% decrease in pain intensity among non-opioid users. Furlan et 
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al. (2006) found that strong opioids were more effective for pain relief and functional outcomes, 
although the drop-out rates averaged 33%. Similarly, a more recent meta-analysis (Noble et al., 
2008) of efficacy and safety of long-term opioid therapy showed that many patients discontinue 
long-term opioid therapy due to adverse events or insufficient pain relief.  
 While numerous studies have examined the efficacy of opioid treatment and the adverse 
side effects, only a limited number of studies examined the role pre-treatment opioids have in 
multidisciplinary rehabilitation treatment outcomes. One set of research originated from the 
Mayo Clinic, which has 3-week outpatient chronic pain rehabilitation center that requires 
mandatory opioid withdrawal during the course of treatment. The first study completed at the 
Mayo Clinic by Rome and colleagues (2004) compared patients taking opioids daily (n=135) to 
patients not taking opioids daily (n=221) at the time of admission. Over the course of the 3-week 
treatment program, opioid use was tapered and discontinued. Researchers found that higher 
morphine equivalent analgesic doses at pre-treatment were associated with a greater probability 
of program dropout. At post-treatment, opioid users reported significantly greater pain severity 
and catastrophizing than non-opioid users. However, measures of interference due to pain, 
perceived life control, affective distress, depression, or general activity level did not differ 
significantly between users and non-opioid users. (Rome, Townsend, Bruce, Sletten, Luedtke, & 
Hodgson, 2004). Hooten et al. (2007) and Townsend and colleagues (2008) found similar results 
among the patients at the Mayo Clinic. Specifically, pre-treatment opioid users and non-users 
demonstrated no significant differences in outcomes immediately following treatment. 
Additionally, Townsend et al. reported no differences between the opioid and the non-opioid 
group at a 6-month follow-up. However, higher doses of opioids was again associated with a 
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higher treatment dropout rate and at the 6-month follow-up 30 of 132 patients (22%) had 
renewed their opioid use. 
 MacLaren and colleagues (2006) examined the effects of pre-treatment and continued 
opioid use on treatment outcomes. Although patients were not mandated to decrease or 
discontinue opioid use, medical management was a part of treatment. Of the 70 participants 
using opioids at admission, 24 (34.3%) reported decreasing their dosage during the course of 
treatment and a total of 14.3% of pre-treatment opioid users had discontinued by the time of 
discharge. Overall, both opioid users and nonusers showed improvements in psychological and 
physical measures and post-treatment outcomes did not differ significantly between the two 
groups. Furthermore, at 6-months post-treatment opioid users did not show significantly different 
return to work rates relative to opioid nonusers. A secondary analysis further indicated no 
difference in improvements on any of the outcome measures across patients who had decreased 
opioid use over the course of treatment and those whose dosage had remained consistent. 
 Finally, Kidner, Mayer, and Gatchel (2009) performed a similar study that included 
mandatory opioid withdrawal and included post-treatment and 12-month follow-up data. The 
results of the opioid and non-opioid analyses were similar to those obtained by previous studies, 
with no differences in outcome for depression, mental and physical health, and the Million 
Visual Analog Scale. However, there were some differences found with non-opioid users having 
lower scores on pain intensity and on the Oswestry Disability Index, and higher 1-year return-to-
work and work retention rates. In addition to the dichotomous variable of opioid use or non-use, 
Kidner and colleagues went on to explore pre-treatment opioid levels based on daily morphine 
equivalent dose: low (<30 mg/d), medium (31–60 mg/d), high (61–120 mg/d), and very high 
(>120 mg/d). A higher pre-treatment opioid dose was associated with a greater risk of 
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noncompletion, which may be attributed to the program's mandatory opioid taper. Additionally, 
higher pre-treatment dosage was associated with lower rates of return to work and work retention 
as well as higher healthcare utilization. Furthermore, at the one year follow-up, patients in the 
Very High subgroup were 11.6 times as likely to be on Social Security Disability Income 
compared with their non-opioid counterparts. 
 Overall, researchers have shown mixed results in the efficacy and risk of long-term 
opioid use for chronic pain patients. While several studies have focused on functional outcome 
measures, the majority of studies have focused on a reduction of pain as the treatment outcome 
(Turk, 1996). Additionally, most studies examining the impact of opioid use on chronic pain 
have not taken into account the varying dosage or examined the effects of continued opioid use 
on outcomes across domains of functioning.  
Current Research Project Aims 
 The use and efficacy of opioids in the treatment of chronic pain remains controversial, as 
the long-term impact is still unknown. Limited research is available on the effects of a 
multidisciplinary pain program on patients who remain on opioids throughout treatment, and 
whether opioid use should be a screening factor for admission to a program. Additionally, there 
is a lack of data on pre-treatment levels of opioid use as it relates to physical, psychological and 
social treatment outcomes. The present study examines pre-treatment level of opioid use as a 
predictor of success in a multidisciplinary pain setting. 
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Hypotheses 
1. Pre-treatment level of opioid use will predict differences in response to treatment, such as 
participants reporting higher level of pre-treatment opioid use will have higher rates of program 
non-completion. 
 
2. Participants with higher levels of pre-treatment opioid use will report higher levels of pre-
treatment depressive symptoms, as measured by scores on the Beck Depression Inventory (BDI). 
 
3. Participants with higher levels of pre-treatment opioid use will report higher levels of pre-
treatment anxiety symptoms, as measured by scores on the Pain Anxiety Symptom Scale 
(PASS). 
 
4. Participants with higher levels of pre-treatment opioid use will report a lower health-related 
quality of life, as measured by scores on the Pain Self-Efficacy Scale (PSEQ) and 10-point sleep 
and pain scales. 
 
5. Participants with higher levels of pre-treatment opioid use will score lower on pre-treatment 
measures of physical functioning, as measured by the physical demand capacity and occasional 
lift weight. 
 
6. Pre-treatment level of opioid use will predict improvements in depressive symptoms, such that 
subjects reporting higher levels of pre-treatment opioid use will report higher levels of post-
treatment depression and show fewer improvements pre-treatment to post-treatment on the BDI. 
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7. Pre-treatment level of opioid use will predict improvements in anxiety symptoms, such that 
subjects reporting higher levels of pre-treatment opioid use will report higher levels of post-
treatment anxiety and show fewer improvements pre-treatment to post-treatment on the PASS. 
 
8. Pre-treatment level of opioid use will predict improvements in health-related quality of life, 
such that those reporting higher levels of pre-treatment opioid use will report lower levels of 
self-efficacy on the PSEQ and higher pain and sleep scores. Those reporting higher levels of pre-
treatment opioid will also show less improvement pre-treatment to post-treatment on the PSEQ, 
sleep scale, and pain scale. 
 
9. Pre-treatment level of opioid use will predict response to treatment, such that subjects 
reporting higher levels of pre-treatment opioid use will demonstrate less improvement in 
physical functioning upon completion of treatment, as measured by physical capacity demand, 
occasional lift, and completion of discharge goals. 
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Method 
Participants 
 Progressive Rehabilitation Associates (PRA) is a multidisciplinary rehabilitation center in 
Portland, Oregon that treats patients with chronic pain disability. Participants in this study were 
all clients treated at PRA and were typically referred either by their attending physician or 
insurer. Patients eligible for treatment at PRA were18 years or older, have met criteria for 
chronic pain, and have the ability and willingness to function and participate in treatment. The 
participants in this study were patients of all injury types admitted between October, 1998 and 
December, 2010. All participants signed an authorization to use, obtain, or disclose protected 
health information (PRA document) that allows for their data to be used for research. 
 
Procedures 
 An intake evaluation was completed for all chronic pain patients, which includes a 
physical examination, a medical history, a psychological intake interview, and a functional 
capacity evaluation. Demographic data was collected during the intake interview. On the first 
day of treatment patients were asked to complete the following instruments: the Beck Depression 
Inventory (BDI; Beck, Ward, Mendelson, Mock, & Erbaugh, 1961); Beck Anxiety Inventory 
(BAI), Pain Anxiety Symptom Scale (PASS), Pain Self-Efficacy Scale (PSEQ), and a 10-point 
pain and sleep scale. Also, patients were assessed by the Physical and Occupational therapy staff 
in order to determine physical and functional capacity and to establish discharge goals. The BDI, 
PASS, PSEQ, PSOCQ, and sleep and pain scales were also administered upon completion of the 
program and discharge goals were reviewed to determine progress. Information regarding 
medication use, including opioid mediation, was also taken at the time of admission. Daily 
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dosage of all medication was obtained through self-report by the patient and later confirmed by 
PRA medical staff with the patient's primary care physician. Once the average daily dose of 
opioid medications was confirmed, it is used to calculate the equianalgesic dosages of morphine 
(MSEQ; Global RPh, 2005; Portenoy et al., 2007). This data was then documented in the 
conference notes and entered into a patient database by PRA management. Patients who reported 
using medication occasionally or prn were excluded from analyses because specific opioid use 
was not able to be determined. Patients were then classified into two groups, those who used 
opioids pre-treatment and their non-opioid counterparts. Patients were then further classified into 
one of five subgroups based on the MSEQ information, NO subgroup (0 mg); LOW subgroup 
(>0-30 mg); MEDIUM subgroup (>30-60 mg); HIGH subgroup (>60-120 mg); and VERY 
HIGH subgroup (>120 mg). 
 
Instruments and Outcome Measures 
Beck Depression Inventory (BDI). The Beck Depression Inventory is a 21-item 
multiple-choice test designed to measure physical and emotional symptoms of depression, and is 
currently one of the most widely used measure of depression in both medical and psychological 
research. It was originally developed by Beck, Ward, Mendelson, Mock, and Erbaugh (1961) 
with the purpose of offering a reliable and valid measure of the presence and/or severity of 
depression. Reliability of the BDI is good, with internal consistency coefficients exceeding .73 in 
nonpsychiatric samples (Beck et al., 1988). Many researchers have demonstrated the validity of 
the measure with chronic pain patients (Geisser, Roth, & Robinson, 1997; Novy, Nelson, Berry, 
& Averill, 1995; Romano & Turner, 1985; Turner & Romano, 1984), although some researchers 
have recommended the removal of several items (Wesley, Gatchel, Garofalo, & Polatin, 1999) 
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and/or modification of depression cutoff scores (Geisser et al., 1997; Wesley et al., 1999) 
because somatic items were confounded with pain symptomatology (Wesley, Gatchel, Polatin, 
Kinney, & Mayer, 1991). 
Pain Anxiety Symptom Scale (PASS). The PASS (McCracken, Zayfert, & Gross, 1992) 
is a self-report scale that evaluates fear and anxiety related to pain. It uses a 6-point Likert-type 
scale with anchors at 0 (“Never”) and 5 (“Always”). The PASS yields four subscales, cognitive 
anxiety, escape/avoidance behaviors, fearful appraisal, physiological anxiety, and a total scale. 
Only the total scale was used in the current study. Previous research has demonstrated the PASS 
to yield four internally consistent subscales with adequate test-retest reliability (McCracken, 
Gross, Sorg, & Edmunds, 1993). The validity of the total and four subscale scores is supported 
by significant positive correlations with measures of general anxiety, pain, and disability 
(McCracken et al., 1992).  
Pain Self-Efficacy Scale (PSEQ). The Pain Self-Efficacy Questionnaire (PSEQ) is a 10-
item short-worded instrument which measures patients’ beliefs about their ability to complete a 
range of daily activities in spite of the presence of pain. (Nicholas, 2007). The reliability and 
validity of the PSEQ have been established and the measure is used widely in clinical chronic 
pain samples. The Cronbach alpha coefficient in the general pain conditions sample was 0.93. 
Patients were asked to rate on a 7-point scale how confident they are that they could currently 
complete various specified tasks despite having pain, with 0 =“not at all confident” to 6 = 
“completely confident.” Responses on each of the items were summed, with a total score ranging 
from 0 to 60, with higher scores indicating higher levels of confidence.  
Sleep and Pain Scales. A self-report sleep scale of 0 to 10, with 0 representing no 
problems with sleep and 10 representing worst possible sleep was given to each patient by a 
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registered nurse. Nursing services also obtained data on the patient’s pain rating, with 0 equaling 
no pain and 10 representing worst possible pain. 
Physical Demand Capacity (PDC). The determination of a patient's physical demand 
capacity is based on maximum lifting capacity from the floor to waist and waist to eye-level. The 
PDC was assessed by an occupational therapist during their initial evaluation. Higher scores 
indicated a higher demand capacity. 
Occasional Lift. Occasional lift is a measure of the amount of weight a patient has 
demonstrated they could lift on occasion. A member of the physical and/or occupational therapy 
team obtained the occasional lift weight at admit and discharge for all patients.  
 
Design and Statistical Analyses 
 The current study was designed to determine the predictive value of pre-treatment level 
of opioid use for treatment outcomes of chronic pain rehabilitation. This study was based on a 
previous study (Kidner, Mayer, & Gatchel, 2009) and examined differences in demographic 
variables and treatment response outcomes as a function of reported level of opioid use. For 
purposes of the study, subjects were divided into two groups and five subgroups based on self-
reported pre-treatment level of opioid use, as gathered from subjects’ medical records. 
Opioid Use and Demographic Variables. Subjects in both the opioid-using and non-
using groups and each subgroup were compared on the following, using analysis of variance: age 
and months since injury. Subjects in both groups and each subgroup were compared on the 
following using Chi-square analyses: gender, race, program completion, type of injury and type 
of insurance. 
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Opioid Use and Psychological/Physical Variables. Univariate analyses of variance 
were used to identify differences between pre-treatment level of opioid use groups and among 
subgroups for the following pre-treatment variables: BDI, PASS, PSEQ, PDC, pain scale, sleep 
scale, physical demand capacity, and occasional lift weight. A univariate analyses of variance 
(ANOVA) was used to identify differences between and among pre-treatment level of opioid use 
groups and subgroups, respectively, for the following post- treatment variables: BDI, PASS, 
PSEQ, PDC, pain scale, sleep scale, physical demand capacity, occasional lift weight, and the 
percentage of goals completed. A linear regression analysis was performed to determine if pre-
treatment level of opioid use was predictive of post-treatment physical and psychological scores. 
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Results 
Demographic Variables 
 Participants in the present study were 365 chronic pain patients of all injury types who 
were referred and consented to a prescribed course of treatment for chronic pain at Progressive 
Rehabilitation Associates (PRA) in Portland, Oregon. The mean age of patients was 45 years 
with a range of 20-81. The gender identification of patients was predominately male (n = 224), 
with 141 female identified patients. The majority of patients were Caucasian (n = 312, 86%);  
41 patients were Hispanic, six patients were African American, four patients were Asian 
American, and two patients identified as having different racial or ethnic membership. The 
average length of injury for patients was 45 months and 75% of all patients completed the 
rehabilitation program. Table 1 includes additional descriptive information about this participant 
sample. 
 
Table 1. Demographic Variables 
Variable Total in sample 
(n) 
Percentage in 
sample (%) 
Program completion  343 94.0 
Injured regions    
             Thoracic/lumbar 175 47.9 
             Upper extremity 56 15.3 
             Multiple musculoskeletal 47 12.9 
             Cervical 43 11.8 
             Lower extremity 36 9.9 
             Other  5 1.4 
             Brain injury 3 0.8 
Insurance   
             Workmen's compensation 341 93.4 
             Commercial insurance 22 6.0 
             Motor vehicle insurance 01 0.3 
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 Data was examined for possible differences in demographic variables between patients 
who used opioids before treatment and non-opioids users. A chi-square analysis revealed 
significant differences for gender and race, but not a significant difference for program 
completion (see Table 2). Gender differed significantly (x2 (1, n = 365) = 4.07, p < .05), with a 
greater number of males using opioids before treatment. Additionally, among patients with pre-
treatment opioid use, there were significantly more Caucasian patients and significantly fewer 
Hispanic patients (x2 (4, n =365) = 10.91, p < .05). There was no significant difference in the 
rate of program completion between the opioid and non-opioid groups. 
 
Table 2. Demographic Variables: Yes and No Groups  
Measures No  
[mean (SD)]  
(n=100) 
Yes 
[mean (SD)]  
(n=265) 
Odds Ratio  
(95% Confidence 
Interval) 
p 
Age  42.76 (10.24) 45.36 (9.44) NA 0.02* 
Length of disability (mo) 42.08 (41.88) 46.48 (49.21) NA 0.44 
     
 % %   
Sex (% male) 53.0 64.5 0.62 (0.39 to 0.99) 0.04* 
Program completion  90.0 94.7 1.99 (0.85 to 4.64) 0.11 
Injured regions      
             Thoracic/lumbar 41.0 50.6 NA 0.14 
             Upper extremity 21.0 13.2   
             Lower extremity 14.0 8.3   
             Multiple musculoskeletal 13.0 12.8   
             Cervical 11.0 12.1   
             Brain injury 0.0 1.1   
             Other  0.0 1.9   
Race    NA 0.03* 
             Caucasian 76.0 89.1   
             Hispanic 19.0 8.3   
             African American 3.0 1.1   
             Other 2.0 1.5   
*p < .05.  
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 Demographic variables were also examined based on the five opioid subgroups: No, 
Low, Medium, High and Very High (see Table 3). The subgroups did not show significant 
differences in gender and rate of program completion. However, there were significant 
differences among subgroups in race, length of disability, and injured region. Racial 
representation varied significantly among the subgroups, x2(16, n =365) = 26.10, p = .05. The 
percentage of Caucasian patients increased as opioid levels increased, from 76.0% in the No 
subgroup to 94.3% in the Very High subgroup. Conversely, the percentage of Hispanic patients 
decreased as opioid levels increased, from 19.0% in the No subgroup to 1.9% in the Very High 
subgroup. Significant difference among the subgroups was also found in the amount of time 
since injury F(4, 346) = 4.59, p < .01. Post-hoc analyses revealed that patients in the Low 
subgroup (M = 29.75) had significantly fewer months since injury than the Very High subgroup  
(M = 67.89).  
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Pre-treatment Psychological/Physical Variables 
 Univariate analyses of variance (ANOVA) were performed to examine differences in pre-
treatment psychological and physical variables between the two opioid use groups (No and Yes) 
and the five subgroups (No, Low, Medium, High, and Very High). Prior to analysis of the 
ANOVAs, the pre-treatment psychological/physical variables were examined for normality. 
Results of Kolmogorov Smirnov (KS) testing for normality showed that BDI (p = .075) and 
PSEQ (p = .254) were normally distributed while PASS (p = .001), sleep (p < .001), pain  
(p < .001), physical capacity (p < .001), and occasional lift (p < .001) variables were not 
normally distributed. However, Stevens (2009) suggests that non-normality only has little effect 
on Type I error when there is a large sample size (> 100). In addition, the assumption of equality 
of variance was assessed for each psychological/physical variable for the two opioid use groups 
and the five subgroups. The results of the Levene’s tests for equality of variance showed that 
only the pain scale had violated equality of variance (p = .009), and thus a more-stringent alpha 
level of .025 was used to assess this ANOVA (Tabachnick & Fidell, 2007). Overall, while 
patients in the No group trended towards more positive outcomes, no significant difference was 
found between the two groups and the five subgroups (see Tables 4 and 5). Finally, an analysis 
of pre-treatment variables demonstrated a high correlation between dependent variables (see 
Table 8), which was also taken into account during analysis. 
 Beck Depression Inventory (BDI). Pre-treatment depression was measured by Beck 
Depression Inventory (BDI), a 21-item self-report measure that assesses physical and emotional 
symptoms of depression. Higher scores on the BDI indicate higher levels of overall emotional 
and physical depression. A univariate analysis of variance (ANOVA) was used to identify 
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differences between the 2 pre-treatment levels of opioid use groups and the five subgroups. 
There was no significant difference in depression scores between the No group  
(M = 20.81, SD = 10.69) and the Yes group (M = 21.15, SD = 10.84), F(1, 362) = 0.71, p = .790. 
Similarly, there was no significant difference in pre-treatment depression scores among the five 
subgroups F(4, 359) = 1.47, p = .21.  
Pain Anxiety Symptom Scale (PASS). Level of anxiety related to pain was measured by 
the Pain Anxiety Symptom Scale (PASS). Higher scores on the PASS indicate higher levels of 
fear and anxiety. A univariate analysis of variance (ANOVA) was used to identify differences 
between the 2 pre-treatment levels of opioid use groups and the five subgroups. No significant 
difference was found between the No group (M = 43.39, SD = 28.43) and the Yes group  
(M = 44.94, SD = 25.60), F(1, 360) = 0.25, p = .620. Similarly, there was no significant 
difference in pre-treatment anxiety scores among the five subgroups F(4, 357) = 0.56, p = .693.  
Pain Self-Efficacy Scale (PSEQ). Patients' belief about their ability to complete daily 
activities in spite of the pain was measured by the Pain Self-Efficacy Scale (PSEQ). Higher 
scores on the PSEQ indicate higher levels of confidence in their ability to complete tasks. A 
univariate analysis of variance (ANOVA) was used to identify differences between the 2 pre-
treatment levels of opioid use groups and the five subgroups. Results indicate the No group  
(M = 27.85, SD = 11.39) exhibited more confidence than the Yes group (M = 26.52, SD = 11.81), 
however, the difference was not significant, F(1, 360) = 0.92, p = .339. Similarly, there was no 
significant difference in pre-treatment self-efficacy scores among the five subgroups  
F(4, 357) = 1.35, p = .252.  
Sleep scale. Patients' quality of sleep was assessed by a 10-point sleep scale, with zero 
representing no problems of sleep and 10 representing worst possible sleep. A univariate analysis 
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of variance (ANOVA) was used to identify differences between the 2 pre-treatment levels of 
opioid use groups and the five subgroups. No significant difference was found between the No 
group (M = 6.60, SD = 2.21) and the Yes group (M = 6.69, SD = 1.92), F(1, 363) = 0.14, p = 
.713. Similarly, there was no significant difference in pre-treatment sleep scores among the five 
subgroups F(4, 360) = 0.79, p = .532. 
Pain scale. Patients' rating of their own pain was also assessed on a 10-point scale, with 0 
equaling no pain and 10 representing worst possible pain. A univariate analysis of variance 
(ANOVA) was used to identify differences between the 2 pre-treatment levels of opioid use 
groups and the five subgroups. The Yes and the No groups rated their pain as a 6.5 out of 10, 
therefore, no significant difference was found between groups, F(1, 363) = 0.04, p = .850. Due to 
the violation in equality of variance, the alpha level of .025 was used for the pain scale for the 
five subgroups. Pre-treatment pain ratings among the five subgroups were also similar, ranging 
from 6.3 to 6.7 out of 10, F(4, 360) = 1.17, p = .323. 
Physical Demand Capacity (PDC). The determination of a patient's physical demand 
capacity is based on maximum lifting capacity from the floor to waist and waist to eye-level. A 
univariate analysis of variance (ANOVA) was used to identify differences between the 2 pre-
treatment levels of opioid use groups and the five subgroups. Similar to the pain scale, no 
difference was found between the No (M = 2.63, SD = 1.25) and Yes groups (M = 2.61,  
SD = 1.39) in regards to physical demand capacity, F(1, 350) = 0.01, p = .907. No significant 
difference was found between subgroups F(4, 347) = 0.51, p = .731. 
 Occasional lift. Occasional lift was measured by the amount of weight a patient 
demonstrated they could lift on occasion. A univariate analysis of variance (ANOVA) was used 
to identify differences between the 2 pre-treatment levels of opioid use groups and the five 
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subgroups. Results indicate the No group (M = 13.72, SD = 6.54) on average lifted less weight 
than the Yes group (M = 14.57, SD = 8.21), however, the difference was not significant, 
 F(1, 357) = 0.84, p = .361. Similarly, there was no significant difference in the occasional lift 
weight among the five subgroups F(4, 357) = 0.55, p = .704  
 
Post-treatment Psychological/Physical Variables. 
 Post-treatment psychological and physical variables were analyzed to identify differences 
between the 2 post-treatment level of opioid use groups (Yes and No) and the five subgroups 
(None, Low, Medium, High, and Very High). Prior to analysis of the ANOVAs and ANCOVAs, 
the post-treatment psychological/physical variables were examined for normality. Results of 
Kolmogorov Smirnov (KS) testing for normality showed that BDI (p = .004), PASS (p < .001), 
PSEQ (p = .044), sleep (p < .001), pain (p < .001), physical capacity (p < .001), occasional lift  
(p < .001) variables, and percentage of goals (p = .003) were not normally distributed. However, 
Stevens (2009) suggests that non-normality only has little effect on Type I error when there is a 
large sample size (> 100). In addition, the assumption of equality of variance was assessed for 
each psychological/physical variable for the two opioid use groups and the five subgroups. The 
results of the Levene’s tests for equality of variance showed that only the PDC scale had violated 
equality of variance (p = .023), and thus a more-stringent alpha level of .025 will be used to 
assess this ANOVA (Tabachnick & Fidell, 2007). Changes in scores from pre-treatment to post-
treatment were also examined for the two groups and five subgroups (see Tables 4 and 5).  
 Beck Depression Inventory (BDI). The Beck Depression Inventory (BDI) was used to 
assess depression after treatment was completed. A univariate analyses of variance (ANOVA) 
and a Analysis of Covariance (ANCOVA) were used to identify differences between patients 
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who used opioids pre-treatment and their non-opioid counterparts. No significant difference was 
found between the No group (M = 11.87, SD = 8.71) and the Yes group (M = 13.89, SD = 10.42), 
F(1, 344) = 2.81, p = .095. There was also no significant difference found between the two 
opioid groups when controlling for pre-treatment BDI scores, F(1, 343) = 3.10, p = .079.  
 However, the opioid subgroups did show significant difference in post-treatment BDI 
scores F(4, 341) = 3.25, p = .012. A post-hoc analysis showed the significance was attributed to 
difference between the No (M = 11.87, SD = 8.71) group and the Very High (M = 16.86,  
SD = 12.24) group and the Low (M = 11.98, SD = 8.53) and Very High groups. Difference was 
still significant when controlling for pre-treatment BDI scores.  
 Pain Anxiety Symptom Scale (PASS). The Pain Anxiety Symptom Scale (PASS) was 
used to assess anxiety after treatment was completed. A univariate analyses of variance 
(ANOVA) was used to identify differences between patients who used opioids pre-treatment and 
their non-opioid counterparts. No significant difference was found between the No group  
(M = 29.81, SD = 27.57) and the Yes group (M = 33.44, SD = 26.16), F(1, 344) = 1.28, p = .258. 
There was also no significant difference found between the two opioid groups when controlling 
for pre-treatment PASS scores, F(1, 341) = 1.84, p = .176. Additionally, among the two opioid 
groups and five subgroups, no significant difference was found in changes in pre-treatment to 
post-treatment PASS scores.  
 Among the opioid subgroups there was no significant difference in post-treatment PASS 
scores F(4, 334) = 2.04, p = .089. Similarly, when controlled for pre-treatment PASS scores, the 
difference between subgroups was not significant F(4, 338) = 1.80 p = .129. 
 Pain Self-Efficacy Scale (PSEQ). The Pain Self-Efficacy Scale was used to assess 
patients’ beliefs about their ability to complete daily activities. A univariate analyses of variance 
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(ANOVA) and an Analysis of Covariance (ANCOVA) were used to identify differences between 
patients who used opioids pre-treatment and their non-opioid counterparts. No significant 
difference was found between the No group (M = 39.02, SD = 12.36) and the Yes group  
(M = 36.73, SD = 12.71), F(1, 344) = 2.27, p = .133. There was also no significant difference 
found between the two opioid groups when controlling for pre-treatment PSEQ scores,  
F(1, 341) = 1.93, p = .166. Additionally, among the two opioid groups and five subgroups, no 
significant difference was found in changes in pre-treatment to post-treatment PSEQ scores.  
 The opioid subgroups showed significant difference in post-treatment PSEQ scores F(4, 
341) = 2.66, p = .033. A post-hoc analysis attributed the difference between the No (M = 39.02, 
SD = 12.36) group and the Very High (M = 33.34, SD = 13.12) group. However, an ANCOVA 
yielded no significant differences among the five opioid subgroups in post-treatment PSEQ 
scores, when controlling for pre-treatment PSEQ scores, F(4, 338) = 1.82, p =.124. 
 Sleep scale. Quality of sleep was assessed by a 10-point sleep scale, with 0 representing 
no problems of sleep and 10 representing worst possible sleep. A univariate analyses of variance 
(ANOVA) and an Analysis of Covariance (ANCOVA) were used to identify differences between 
patients who used opioids pre-treatment and their non-opioid counterparts. No significant 
difference was found between the No group (M = 5.29, SD = 2.21) and the Yes group (M = 5.66, 
SD = 2.14), F(1, 354) = 2.14, p = .145. There was also no significant difference found between 
the two opioid groups when controlling for pre-treatment sleep scores, F(1, 353) = 2.06, 
 p = .152. Additionally, among the two opioid groups and five subgroups, no significant 
difference was found in changes in pre-treatment to post-treatment sleep scores.  
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 Among opioid subgroups, sleep rating scores increased as the level of opioid use 
increased, however, the difference was not significant F(4, 351) = 2.14, p = .075. There was also 
no difference when controlling for pre-treatment sleep scores.  
 Pain scale. Self-reported level of pain was assessed by a 10-point sleep scale, with 0 
representing no pain and 10 representing worst possible pain. A univariate analyses of variance 
(ANOVA) and an Analysis of Covariance (ANCOVA) were used to identify differences between 
patients who used opioids pre-treatment and their non-opioid counterparts. No significant 
difference was found between the No group (M = 5.97, SD = 1.60) and the Yes group (M = 6.08, 
SD = 1.66), F(1, 354) = 0.31, p = .576. There was also no significant difference found between 
the two opioid groups when controlling for pre-treatment pain scores, F(1, 353) = 0.45, p = .504. 
Additionally, among the two opioid groups and five subgroups, no significant difference was 
found in changes in pre-treatment to post-treatment pain scores.  
 Among the opioid subgroups there was also no significant difference in post-treatment 
pain scale rating F(4, 351) = 1.92, p = .106. Similarly, when controlled for pre-treatment pain 
scores, the difference between subgroups was not significant F(4, 350) = 2.25, p = .064. 
 Physical Demand Capacity (PDC). The maximum lifting capacity from the floor to 
waist and waist to eye-level was used to determine a patient's physical demand capacity. A 
univariate analyses of variance (ANOVA) and an Analysis of Covariance (ANCOVA) were used 
to identify differences between patients who used opioids pre-treatment and their non-opioid 
counterparts. Due to the violation in equality of variance, the more stringent alpha level of .025 
was used for the ANOVA/ANCOVA using the two opioid groups. No significant difference was 
found between the No group (M = 3.49, SD = 1.17) and the Yes group (M = 3.60, SD = 1.36),  
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F(1, 349) = 0.46, p = .497. There was also no significant difference found between the two 
opioid groups when controlling for pre-treatment physical demand capacity, F(1, 345) = 1.13, 
 p = .288. Additionally, among the two opioid groups and five subgroups, no significant 
difference was found in changes in pre-treatment to post-treatment physical demand scores.  
Among the opioid subgroups there was also no significant difference in post-treatment physical 
demand capacity F(4, 346) = 0.19, p = .943. Similarly, when controlled for pre-treatment pain 
scores, the difference between subgroups was not significant F(4, 342) = 0.57, p = .688. 
Occasional lift. Occasional lift was measured by the amount of weight a patient 
demonstrated they could lift on occasion. A univariate analyses of variance (ANOVA) and an 
Analysis of Covariance (ANCOVA) were used to identify differences between patients who used 
opioids pre-treatment and their non-opioid counterparts. The No group (M = 19.62, SD = 8.08) 
lifted slightly less weight than the Yes group (M = 20.83, SD = 10.04), however, no significant 
difference was found, F(1, 357) = 1.14, p = .288. There was also no significant difference found 
between the two opioid groups when controlling for pre-treatment occasional lift weight,  
F(1, 355) = 0.23, p = .631. Additionally, among the two opioid groups and five subgroups, no 
significant difference was found in changes in pre-treatment to post-treatment occasional lift 
weight.  
Among the opioid subgroups there was also no significant difference in post-treatment 
occasional lift F(4, 354) = 0.44, p = .782. Similarly, when controlled for pre-treatment 
occasional lift, the difference between subgroups was not significant F(4, 352) = 0.20, p = .940. 
Goals obtained. The percentage of goal obtained refers to the goals laid out for each 
patient in their treatment plan. These goals include meeting lift weight, improved conditioning 
time, flexibility, sit/stand/walk goals, relaxation practice and biofeedback goals, and medication 
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management goals. Percentage of total goals met is calculated for each patient, with a 100% 
meeting all treatment goals. A univariate analyses of variance (ANOVA) was used to identify 
differences between patients who used opioids pre-treatment and their non-opioid counterparts. 
No significant difference was found between the No group (M = 81.95, SD = 15.63) and the Yes 
group (M = 81.84, SD = 13.16), F(1, 363) = 0.01, p = .943. Among the opioid subgroups there 
was also no significant difference in the percentage of goals obtained, F(4, 360) = 1.09, p = .363. 
Effect of Decreasing Opioid Use  
 Although patients at PRA were not mandated to withdrawal from opioids, reduction in 
use was recommended and medical staff monitored the taper process for those participants who 
agreed. In order to assess if decreasing opioids had an effect on treatment outcomes, univariate 
analyses of variance (ANOVA) and analyses of covariance (ANCOVA) were used to identify 
differences between patients who voluntarily decreased opioid usage and those who maintained 
or increased use (see Table 6). 
 Univariate analyses of variance on pre-treatment measures (BDI, PASS, PSEQ, Sleep 
Scale, Pain Scale, and PDC) showed no significant difference at the start of treatment between 
individuals who maintained opioid dose and those who decreased. However, a significant main 
effect of opioid use was found for the occasional lift measure, indicating opioid decreasers  
(M  = 15.70, SD  = 8.53) were able to lift significantly more weight than opioid maintainers  
(M = 13.63, SD = 7.84) at the start of treatment F(1, 260) = 4.17, p = .04. Both groups showed 
significant improvement during treatment and at discharge the differences remained constant 
with opioid decreasers continuing to lift more weight than opioid maintainers F(1, 260) = 3.98,  
p = .047. 
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 Significant group differences were also noted by ANCOVA among the two groups for 
post-treatment PASS scores, F(2, 248) = 4.76, p = .030. The opioid decreasers were found to 
have lower fear and anxiety related to pain (M = 31.44, SD = 25.84), compared to their continued 
use counterparts (M = 34.83, SD = 26.36), when controlling for pre-treatment PASS scores 
 F(2, 248) = 4.76, p = .030 . Similar findings were found on a measure of perceived self-efficacy, 
whereby opioid decreasers had a higher level of self-efficacy than those patients who maintained 
or increased their dosage, when controlling for pre-treatment PSEQ scores F(2, 248) = 4.24, 
 p = .041. 
 
 
Table 4. Pre-Admission and Post-Treatment Variables 
Measures No  
[mean (SD)]  
(n=100) 
Yes 
[mean (SD)]  
(n=265) 
F p 
Pre-admission (n = 365)     
             Beck Depression Inventory 20.81  (10.69) 21.15  (10.84) 0.71 0.79 
             Pain Anxiety Symptom Scale 43.39  (28.43) 44.94  (25.60) 0.25 0.62 
             Pain Self-Efficacy Scale 27.85  (11.39) 26.52  (11.81) 0.92 0.34 
             Sleep Quality 6.60  (2.21) 6.69  (1.92) 0.14 0.71 
             Pain Intensity 6.49  (1.51) 6.52  (1.42) 0.04 0.85 
             Physical Demand  2.63  (1.25) 2.61  (1.39) 0.01 0.91 
             Occasional Lift 13.72  (6.54) 14.57  (8.21) 0.84 0.36 
Post-treatment ANCOVA (n = 356)      
             Beck Depression Inventory 11.87  (8.71) 13.89  (10.42) 3.10 0.08 
             Pain Anxiety Symptom Scale 29.81  (27.57) 33.44  (26.16) 1.84 0.18 
             Pain Self-Efficacy Scale 39.02  (12.36) 36.73  (12.71) 1.93 0.17 
             Sleep Quality 5.29  (2.21) 5.66  (2.14) 2.06 0.15 
             Pain Intensity 5.97  (1.60) 6.08  (1.66) 0.45 0.51 
             Physical Demand  3.49  (1.17) 3.60  (1.36) 1.13 0.29 
             Occasional Lift 19.72  (8.06) 20.83  (10.04) 0.23 0.63 
             Goals Obtained (%) 81.95  (15.63) 81.84  (13.16) 0.01 0.94 
54 
 
 
 
 
 
55 
 
Table 6. Pre-Admission and Post-treatment Scores for Patients Maintaining Dose and Decreasing Dose of 
Opioids at Discharge 
 
Measures 
Decreasing  
Dosage  
(n=120) 
Maintaining/ 
Increasing Dosage 
(n=145) F p 
Pre-admission      
            Beck Depression Inventory 22.06 (11.15) 20.39  (10.55) 1.55 0.21 
            Pain Anxiety Symptom Scale 46.34  (25.06) 43.78  (26.06) 0.66 0.42 
            Pain Self-Efficacy Scale 25.60  (11.64) 27.29  (11.93) 1.35 0.25 
            Sleep Quality 6.78  (1.98) 6.61  (1.88) 0.55 0.46 
            Pain Intensity 6.56  (1.37) 6.48  (1.46) 0.23 0.64 
            Physical Demand  2.74  (1.42) 2.50  (1.35) 1.88 0.17 
             Occasional Lift 15.70 (8.53) 13.63  (7.84) 4.17  0.04* 
Post-treatment      
            Beck Depression Inventory 13.89  (11.10) 13.90  (9.87) 1.60 0.21 
            Pain Anxiety Symptom Scale 31.44  (25.84) 34.83  (26.36) 4.76   0.03* 
            Pain Self-Efficacy Scale 37.65  (13.36) 35.93 (12.18) 4.24   0.04* 
            Sleep Quality 5.88  (2.17) 5.48  (2.10) 1.53 0.22 
            Pain Intensity 6.11 (1.77) 6.05 (1.57) 0.00 0.97 
            Physical Demand  3.81  (1.40) 3.42  (1.31) 3.17 0.08 
            Occasional Lift 22.71  (10.95) 19.27  (8.96) 3.98   0.05* 
            Goals Obtained (%) 83.21  (11.53)  80.70  (14.31) 2.40 0.12 
           *p< .05.  
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Linear regression. 
 This study sought to examine if amount of pre-treatment opioid use predicted post-
treatment psychological and physical outcomes. Linear regressions were used to evaluate pre-
treatment levels of opioid use as a predictor of post-treatment psychological and physical 
variables (see Table 7).  
 Beck Depression Inventory (BDI). A linear regression analysis was conducted to 
determine if the amount of pre-treatment opioid use was a predictor of post-treatment depression 
scores, as measured by the BDI. Results indicated that the pre-treatment dose of opioid 
significantly predicted post-treatment BDI scores, F(1, 344) = 9.22, p < .001 and accounted for 
approximately 2.6% of the variance. 
 Pain Anxiety Symptom Scale (PASS). A linear regression analysis was conducted to 
determine if the amount of pre-treatment opioid use was a predictor of post-treatment anxiety 
scores, as measured by the PASS. Results indicated that the pre-treatment dose of opioid 
significantly predicted post-treatment PASS scores, F(1, 344) = 5.69 p < .05 and accounted for 
approximately 1.6% of the variance. 
 Pain Self-Efficacy Scale (PSEQ). A linear regression analysis was conducted to 
determine if the amount of pre-treatment opioid use was a predictor of patients’ beliefs about 
their ability to complete daily activities, as measured by the PSEQ. Results indicated that the pre-
treatment dose of opioid significantly predicted post-treatment PSEQ scores, F(1, 344) = 9.87,  
p < .001 and accounted for approximately 2.8% of the variance. 
 Pain Scale. A linear regression analysis was conducted to determine if the amount of pre-
treatment opioid use was a predictor of patients' post-treatment pain ratings, as measured by  
57 
 
10-point pain scale. Results indicated that the pre-treatment dose of opioid significantly 
predicted post-treatment pain scores, F(1, 354) = 5.96, p < .05 and accounted for approximately 
1.4% of the variance. 
 Sleep Scale. A linear regression analysis was conducted to determine if the amount of 
pre-treatment opioid use was a predictor of patients' post-treatment sleep ratings, as measured by 
10-point sleep scale. Results indicated that the pre-treatment dose of opioid did not significantly 
predict post-treatment sleep scores, F(1, 354) = 2.35, p = 0.13. 
 Physical Demand Capacity (PDC). A linear regression analysis was conducted to 
determine if the amount of pre-treatment opioid use was a predictor of patients’ maximum lifting 
capacity, as measured by the PDC. Results indicated that the pre-treatment dose of opioid did not 
significantly predict post-treatment PDC scores, F(1, 349) = 2.00, p = 0.16. 
 Occasional lift. A linear regression analysis was conducted to determine if the amount of 
pre-treatment opioid use was a predictor of the amount of weight patients could lift on occasion. 
Results indicated that the pre-treatment dose of opioid significantly predicted post-treatment 
occasional lift weight, F(1, 357) = 1.98, p = 0.16.  
 Goals obtained. A linear regression analysis was conducted to determine if the amount 
of pre-treatment opioid use was a predictor of the percentage of goals obtained. Results indicated 
that the pre-treatment dose of opioid did not significantly predict the percentage of goals 
obtained during treatment, F(1, 363) = 0.85, p = 0.36.  
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Table 8. Correlation Between Pre-treatment Variables
Measures 1 2 3 4 5 6
  1.  Beck Depression -
   2. Pain Anxiety Symptom    .594** -
   3. Pain Self-Efficacy Scale   -.518**  -.527** -
   4. Sleep Quality    .235**   .227** -.123* -
   5. Pain Intensity .115*  .140**  -.229**      .196** -
   6. Physical Demand -.130* -.140**   .271** -.030 -.228** -
   7. Occasional Lift -.106*  -.129**   .203**  .002 -.181** .835**
*p< .05.   **p< .01
Table 7. Summary of Linear Regression Analysis for Outcome Measures based on MSEQ
Measures B SE (B) β p
Post-treatment 
   Beck Depression 0.02 0.01 0.16     0.00**
   Pain Anxiety Symptom 0.04 0.02 0.13   0.02*
   Pain Self-Efficacy Scale -0.02 0.01 -0.17     0.00**
   Sleep Quality 0.00 0.00 0.08 0.13
   Pain Intensity 0.00 0.00 0.12   0.03*
   Physical Demand 0.00 0.00 -0.08 0.16
   Occasional Lift -0.01 0.01 -0.07 0.16
   Goals Obtained (%) -0.01 0.01 -0.05 0.36
*p< .05.   **p< .01
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Discussion 
 This study was designed to examine pre-treatment level of opioid use as a predictor of 
success in a multidisciplinary pain setting. Researchers have shown mixed results regarding the 
impact opioid use has on functional rehabilitation programs. Participants in the current study 
were patients who were referred and treated for chronic pain at Progressive Rehabilitation 
Associates (PRA) in Portland, OR. Subjects who entered treatment using opioids to manage pain 
were predominately male, Caucasian, and significantly older than non-opioid users.  
 Analysis also revealed that among the opioid subgroups, participants in the Low opioid 
subgroup (M = 35.76) had significantly fewer months of injury than those in the Very High 
opioid subgroup (M = 94.3 months). This disparity in the length of injury could be attributed to 
opioid tolerance and opioid-induced hyperalgesia (OIH), as opioid therapy for chronic pain may 
paradoxically sensitize patients to acute pain (Compton, 1994; Savage, 1999; Schofferman, 
1993). Mitra (2008) found a strong association between high-grade tolerance and the 
development of OIH. Researchers suggest that morphine use can cause neuronal cell death, 
which could be a contributory factor in the development of tolerance and OIH. In a study by 
Hooten and colleagues (2010), the association between heat pain perception and opioid levels in 
a 109 chronic pain patients was examined. The participants were all enrolled in an outpatient 
multidisciplinary rehabilitation program and were undergoing opioid tapering. Standardized 
values of heat pain perception were obtained one day following program admission and 
following completion of the opioid taper. Researchers showed that a greater baseline morphine 
equivalent dose was associated with greater hyperalgesic values. The results remained significant 
after adjusting for pain severity, pain duration, and pain diagnosis.  
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 Other researchers have also supported the theory that continued opioid use for chronic 
pain induces opioid tolerance and pain sensitivity. Hay and colleagues (2009) found that patients 
using opioids to treat chronic pain were hyperalgesic when assessed by the cold pressure test. 
Cohen et al. (2008) evaluated 355 patients on a steady regimen of opioid medications and found 
that both opioid dose and duration of treatment directly correlated with pain intensity and 
unpleasantness scores compared with patients not receiving opioid treatment. 
 The first hypothesis that pre-treatment levels of opioid use would predict differences in 
response to treatment, such as participants reporting higher level of pre-treatment opioid use 
would have higher rates of program non-completion was not supported. Participants in both 
groups had high rates of program completion, with 90% of the No group completing treatment 
and 94.7% of the Yes group completing the program. Overall, completion rate for the sample 
was 94%, which is higher than previous studies (Kidner, Mayer, & Gatchel, 2009; Rome, 
Townsend, Bruce, Sletten, Luedtke, & Hodgson, 2004).  
One explanation for this finding may be the high percentage of patients covered by 
workmen's compensation insurance (94%). Typically, if patients were referred by their case 
worker, they must complete the program in order to continue receiving workmen's compensation 
benefits. Another contributing factor may be that unlike other studies, the participants in this 
study were not mandated to discontinue opioid use during treatment. Additionally, it should be 
noted that the patient’s pre-treatment level of opioid use was based, in part, on self-report. As 
with other substances, patients might under-report their level of use. Medical records were used 
to verify patient's report; however, opioid misuse among patients may be possible. Objective 
measurements of current opioid use at the beginning and throughout the program may be a 
further avenue for future research to explore. 
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 The second hypothesis that participants with higher levels of pre-treatment opioid use 
would report higher levels of pre-treatment depressive symptoms, as measured by scores on the 
Beck Depression Inventory (BDI) was not supported. Both the Yes group (M = 21.2) and the No 
group (M = 20.8) reported moderate levels of pre-treatment depression. Similarly, there was no 
significant difference in pre-treatment depression scores among the five subgroups; however, the 
Low group reported less depressive symptoms than the No, Medium, High or Very High groups. 
Although research on pre-treatment depression has been mixed, participants in the current study 
reported overall higher depression scores than other studies across both groups and all 
subgroups, which may account for the findings. 
 MacLaren et al. (2006) found similar results, noting no significant difference on pre-
treatment BDI scores among opioid users and non-users. Although it should be noted, that only 
patients who completed treatment were included in the analysis and data from patients who did 
not complete the program was not available. However, the current study faced the same 
limitation, as that pre-treatment findings were based on both completers and non-completers of 
the multidisciplinary treatment program, while post-treatment outcomes were based on only 
patients who completed the program. Although, the current study had a 94% completion rate, 
conclusions regarding the role of pre-treatment level of opioid use may only be generalizable to 
patients who complete treatment programs. 
 Conversely, Kidner (2007) found that on both self-report and clinician-report measures of 
depression, the Yes group scored significantly higher than the No group. A subgroup analysis 
found that the Very High group reported depressive symptoms in the moderate to severe range; 
however, clinicians scored them in the mild to moderate range on the HAM-D. Kidner 
hypothesized this discrepancy may be related to the Very High subgroup’s tendency to over 
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report symptoms or the clinicians bias that subgroup over reports, therefore underrating their 
symptoms. 
 For the current study, an analysis of post-treatment depression scores revealed significant 
difference in post-treatment BDI scores among the 5 subgroups. A post-hoc analysis showed the 
significance was attributed to a difference between the No (M = 11.87, SD = 8.71) group and the 
Very High (M = 16.86, SD = 12.24) group and between the Low (M = 11.98, SD = 8.53) and 
Very High groups. This difference was still significant when controlling for pre-treatment BDI 
scores.  
 Similar to the depression findings, participants with higher levels of pre-treatment opioid 
use did not report significantly higher anxiety symptoms prior to treatment, as measured by the 
Pain Anxiety Symptom Scale (PASS). Specifically, the Yes group reported slightly higher pain-
related anxiety symptoms (M = 44.94), compared to the No group (M = 43.39). Among the 
opioid subgroups there was also no significant difference in post-treatment PASS scores. 
Similarly, when controlled for pre-treatment PASS scores, the difference between subgroups was 
not significant. 
 Researchers suggest that anxiety is an important emotional and physiological component 
of chronic pain (Burns et al., 2000; Vowles et al., 2004). Heightened pain-related anxiety is 
associated with maladaptive coping responses, medication use, and occupational disability 
(McCracken et al., 1992). The Pain Anxiety Symptoms Scale (PASS, McCracken et al., 1992) 
assesses several dimensions of pain-related anxiety with four subscale scores: (a) cognitive 
anxiety symptoms related to the experience of pain (“I find it hard to concentrate when I hurt” 
(b) escape and avoidance responses intended to reduce pain (“I try to avoid activities that cause 
pain”), (c) fearful appraisals of pain (“Pain sensations are terrifying”), and (d) pain-related 
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physiological anxiety symptoms (“Pain makes me nauseous”; Larsen et al., 1997; Vowles et al; 
2004). Higher PASS scores have been related to greater pain anxiety relative to matched control 
groups, over prediction of pain intensity, poorer coping responses, higher levels of general 
anxiety and self-reported disability (Crombez et al., 1999a; McCracken et al., 1996, 1998). 
Recently, the PASS has also been linked with physical capacity variables (Burns et al., 2000). 
The current study utilized the total composite PASS score, as the four subscales were not 
available for analysis.  
 The fourth hypothesis that participants with higher levels of pre-treatment opioid use 
would report a lower health-related quality of life, as measured by scores on the Pain Self-
Efficacy Scale (PSEQ) and 11-point sleep and pain scales was also not supported. Patients in No 
opioid group (M = 27.85) reported higher confidence in their abilities over the Yes group  
(M = 26.52); however, the difference was not significant. Similarly, an analysis of post-treatment 
data showed no significant difference in PSEQ scores at treatment end among the opioid 
subgroups, F(4, 341) = 2.66, p = .033. Patients in both groups rated their pre-treatment quality of 
sleep (M = 6.6/10) and pain intensity (M = 6.5/10) approximately the same. Additionally, no 
significant difference was found across subgroups. Therefore, patients who used opioids to 
control pain reported similar pain intensity as those who did not use opioids to control their pain. 
Pre-treatment physical functioning, as measured by the physical demand capacity 
measure and occasional lift, was not significantly affected by pre-treatment opioid use. The 
physical demand capacity was virtually even across groups and ranged from 2.45 to 2.72. 
Patients in the Low opioid subgroup demonstrated the highest occasional lift (15.13 lbs), while 
the Very High group showed the lowest amount of weight lifted (13.64). Post-treatment analysis 
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of data revealed similar patterns, indicating that pre-treatment use of opioids does not 
significantly affect physical functioning outcomes. 
The sixth hypothesis proposed that pre-treatment levels of opioid use will predict 
improvements in depression symptoms, such that subjects reporting higher levels of pre-
treatment opioid use will report higher levels of post-treatment depression and show fewer 
improvements pre-treatment to post-treatment on the BDI. A linear regression analysis supported 
this hypothesis, as results indicated that the pre-treatment dose of opioid significantly predicted 
post-treatment BDI scores, F(1, 344) = 9.22, p < .001 and accounted for approximately 2.6% of 
the variance. It should be noted that the current study was not able to control for patients who 
were taking antidepressants at the start of treatment or for those patients who were started on 
antidepressant during the course of treatment. 
These results are similar to other studies, which found patients with chronic pain who 
take opioids regularly have a higher occurrence of depression compared with those who do not 
take opioids (28% vs. 19%, p = 0.012) (Jensen, Thomsen, & Hojsted, 2006). Braden and 
colleagues (2009) found that patients who received a depression diagnosis in the prior 2 years 
were three times more likely to be prescribed and use opioids for chronic pain management 
compared to patients with no history of depression. In addition, those with a history of 
depression and with long-term opioid use were also more likely to receive higher daily doses, 
greater day’s supply, more potent Schedule II opioids and were more likely to have concurrent 
use of sedative-hypnotic medications than persons without a history of depression. Overall, 
researchers have shown that a bidirectional relationship exists between depression and opioid use 
among people with chronic pain (Braden et al., 2009; Breckenridge & Clark, 2003; Ciccone et 
al., 2000; Jensen, Thomsen, & Hojsted, 2006). 
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Jensen and colleagues (2006) conducted a 10-year follow-up study of people who 
received multidisciplinary chronic pain treatment and they found that people taking opioids 10 
years post-inpatient treatment were more likely to be depressed than those who were not taking 
opioids. There are several theories investigating the mechanism of opioid and depression. Wasan 
et al. (2005) hypothesized that depression and anxiety are associated with reduced opioid 
analgesia in people with chronic pain. Long-term opioid use may also affect neurotransmitters, 
the immune system, sex steroids, the HPA axis, sleep, and cognitive function, which effect 
mood. Further research is needed to decipher the effects from opioid and the effects from chronic 
pain (Darnall, Stacey, & Chou, 2012). 
The seventh hypothesis that pre-treatment level of opioid use will predict improvements 
in anxiety symptoms, such that subjects reporting higher levels of pre-treatment opioid use will 
report higher levels of post-treatment anxiety and show fewer improvements pre-treatment to 
post-treatment on the PASS was supported. A linear regression analysis indicated that the pre-
treatment dose of opioid significantly predicted post-treatment PASS scores, F(1, 344) = 5.69,  
p < .05 and accounted for approximately 1.6% of the variance. 
Like depression, anxiety has a complex and multifaceted relationship with pain and 
researchers have found that anxiety is directly related to opioid use. Particularly, heightened 
pain-related anxiety has been associated with maladaptive coping responses, medication use, and 
occupational disability (McCracken et al., 1992). Demyttenaere et al. (2007) studied privately 
insured and Medicare patients and found that among privately insured individuals, a diagnosis of 
anxiety disorder predicted heavy opioid utilization. In a large population study (n = 9,279), 
Sullivan et al. (1998) showed that chronic pain patients with a diagnosis of panic disorder or 
generalized anxiety within the last year were significantly more likely to report regular use of 
66 
 
prescription opioids. Specifically, patients with a diagnosis of panic disorder in the last year were 
six times more likely to use opioids regularly and those with a generalized anxiety diagnosis 
were four times as likely compared to non-opioid users. 
Several researchers have tried to ascertain the reason for the greater opioid use among 
patients with anxiety; however, a consensus has not been found. Colasanti et al. (2011) theorized 
that stimulation of κ-opioid receptors (KORs) leads to anxiolytic responses similar to 
benzodiazapines in both healthy individuals and those with an anxiety disorder. Therefore, the 
use of opioids among chronic pain patients may serve as an adaptive function to mitigate anxiety 
symptoms. This theory supports the results of the current study, whereby non-opioid patient and 
those on lower doses may learn more adaptive and long-term techniques to control their anxiety 
and those on higher doses continue to use opioids to manage anxiety symptoms on a short-term 
base. Further clinical studies are needed to assess the effects of opioid use on anxiety among 
chronic pain patients. 
 The hypothesis that pre-treatment levels of opioid would predict improvements in health-
related quality of life, such that those reporting higher levels of pre-treatment opioid reported 
lower levels of self-efficacy on the PSEQ and higher pain and sleep scores was partially 
supported. Results indicated that the pre-treatment dose of opioid significantly predicted post-
treatment PSEQ scores, F(1, 344) = 9.87, p < .001 and accounted for approximately 2.8% of the 
variance. However, a linear regression analysis on pre-treatment opioid use on pain and sleep 
scores was not found to be significant. 
 Self-efficacy has been defined as a sense of personal control and the perception that one 
has the ability to minimize, reduce, or tolerate a particular situation (Bandura, 1977). Lefebvre et 
al. (1999) found that self-efficacy was influential in improving adaptation to pain, increasing 
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pain tolerance, improving pain-related disability and encouraging more active coping techniques. 
Coping strategies that are often taught in multidisciplinary pain treatment facilities, such as 
cognitive restructuring, psychoeducation, self-relaxation, in addition to placebos, have all been 
found to increase perceived self-efficacy to cope with pain. Bandura and colleagues (1987) 
reported that the cognitive techniques were the most effective and those patients who perceived 
themselves as self-efficacious, the higher their pain threshold and tolerance levels were and the 
less pain they experienced during a later cold pressure test. Holroyd and his colleagues (1984) 
demonstrated that perceived self-efficacy predicted reduction in tension headaches, whereas the 
actual amount of control over muscular activity achieved in treatment was unrelated to the 
incidence of subsequent headaches. These results are consistent with the current findings, as 
patients who are on no or low doses of opioids, may be more open to learning active coping 
strategies compared to patients who rely heavily on opioids for pain management.  
 Similar to previous studies examining pre-treatment opioid use, self-reported measures of 
sleep and pain were not found to be significant among opioid and non-opioid users. Both groups 
and all subgroups showed significant decrease in self-reported measures at post-treatment; 
however, opioid users described similar pain intensity levels as those who were not on opioids.  
 The hypothesis that pre-treatment level of opioid use will predict response to treatment, 
such that subjects reporting higher levels of pre-treatment opioid use will demonstrate less 
improvement in physical functioning upon completion of treatment, as measured by physical 
capacity demand, occasional lift, and completion of discharge goals was only partially supported. 
Pre-treatment opioid use was a predictor of the amount of weight patients could lift on occasion, 
F(1, 357) = 1.98, p = 0.16. Conversely, pre-treatment opioid use was not found to be a predictor 
of patients’ maximum lifting capacity, as measured by the physical demand capacity,  
68 
 
F(1, 349) = 2.00, p = 0.16. Finally, opioid use prior to treatment was found not to be a predictor 
of the percentage of goals obtained, F(1, 363) = 0.85, p = 0.36.  
 There have been several studies examining physical outcomes of multidisciplinary 
chronic pain treatment; however, only a few reported on opioid use and only one examined the 
relations between opioid use and objective physical treatment outcomes. One of the early studies 
conducted by Maruta and Swanson (1981) found that opioid users fared more poorly in treatment 
than did nonusers. However, treatment success was defined by three criteria: (a) modification in 
attitude; (b) reduction in medication; (c) improvement in physical functioning. At discharge, staff 
members subjectively rated patients on these criteria based on a 3-point scale. Researchers found 
a significantly greater proportion of nonoxycodone users were classified as treatment successes 
than their oxycodone counterparts. However, it should be noted that medication reduction was 
33% of treatment success, therefore, an analysis of pure functional gains was unavailable. 
MacLaren et al. (2008) addressed these issues by assessing participants' physical abilities via a 
standardized functional capacity evaluation (FCE), specifically participants’ ability to lift from 
the floor to waist level (floor-to-waist lift). MacLaren and colleagues found patients taking 
opioids at admission to a multidisciplinary treatment program showed post-treatment 
improvements at the same level of non-opioid users. 
 The current study had mixed results, as pre-treatment opioid use was a predictor of 
occasional lift measures; however, it was not a predictor for patients’ maximum lifting capacity. 
One possible reason for this discrepancy may be that 93% of the current study's participants were 
involved with worker's compensation and many were mandated to multidisciplinary treatment in 
order to maintain compensation. Therefore, motivations for secondary gains were not able to be 
accounted for in the current study. Additional studies with a more representative sample of 
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chronic pain patients who are not currently active with worker’s compensation insurance claims 
may be warranted.  
 Finally, unlike previous studies evaluating the effect of pre-treatment opioid use on 
multidisciplinary treatment outcomes, the current study did not mandate that participants  
completely withdraw from opioids during the course of treatment. Therefore, the effect of 
continued opioid use during treatment was able to be examined. To date, MacLaren and 
colleagues (2008) have conducted the only study to my knowledge that examined the effect of 
continued opioid use during treatment. Similar to MacLaren, no significant differences were 
found on pre- or post-treatment measures of depression, pain severity, sleep quality, and physical 
capacity between individuals who maintained opioid dosage and those who decreased. However, 
a significant main effect of opioid use was found on a pre-treatment occasional lift measure, 
indicating opioid decreasers (M = 15.70, SD = 8.53) were able to lift significantly more weight 
than opioid maintainers (M = 13.63, SD = 7.84) at the start of treatment F(1, 260) = 4.17, p = .04. 
Additionally, the current study found significant post-treatment group differences were found on 
a measure of pain-related anxiety (F(2, 248) = 4.76, p = .030) and on a measure of perceived 
self-efficacy (F(2, 248) = 4.24, p = .041), when controlling for pre-treatment scores. This is in 
contrast to MacLaren and colleagues, who found no differences at discharge on measures of pain 
severity, depression, disability, performance on a floor-to-waist lifting task or on any of the 
outcome measures across patients who had decreased opioid use over the course of treatment and 
those whose dosage had remained consistent.  
 One possible explanation for this discordant finding is the differing sample size and 
characteristics of participants. Both studies consisted of a majority of participants who were 
referred for treatment due to work-related injuries and were largely involved with worker's 
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compensation insurance; however, the current study's participants had an average length of 
injury of 44 months; which is almost double MacLaren's participants (23 months).  The current 
study also consisted of a total sample size of 365 participants, 265 (72.6%) of whom were taking 
opioid at the start of treatment. During the course of treatment, 120 (45.3%) of these participants 
decreased their opioid use and 24 (11.3%) reported discontinuing their use all together. This is 
compared to MacLaren's smaller sample size of 127 total participants, of which only 55.2% 
reported using opioids at the start of treatment. During the course of treatment, 24 (34.3%) 
participants reported a decrease in opioid use, of which 10 (14.3%) participants discontinued use 
all together.  The higher rate of pre-treatment opioid use and the higher percentage of 
participants who continued use during the course of treatment may explain why significant 
differences in post-treatment measurements were found. Additionally, the current study 
examined measures such as fear and anxiety related to pain and perceptions of self-efficacy, both 
measurements not examined in previous studies. Future studies where participants are randomly 
assigned to opioid use conditions may be warranted in order to further exam the effect of 
continued opioid use during treatment. 
Overall, patients in the current study who entered treatment on lower levels of opioids 
demonstrated greater improvement in depression compared to patients on higher levels of pre-
treatment opioids. However, across all other measures, patients who reported pre-treatment 
opioid use showed similar benefits from multidisciplinary pain treatment compared to patients 
who reported no pre-treatment opioid use. Pre-treatment opioid use was found to be a successful 
predictor of post-treatment BDI, PASS, and PSEQ scores and those patients who decreased their 
opioid use during treatment demonstrated significantly greater improvement on measures of 
anxiety and self-efficacy compared to those who maintained their dosage.  Additionally, it is 
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important to note that opioid users did not report decreased pain levels or improved functioning 
at the start or end of treatment, which would have been expected for patients using opioids to 
control pain.  
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Beck Depression Inventory 
 
Choose the one statement, from among the group of four statements in each question that best describes 
how you have been feeling during the past few days.  Circle the number beside your choice.  
 
1        0     I do not feel bad. 
       1     I feel sad. 
       2     I am sad all the time and I can’t snap out of it. 
       3     I am so sad or unhappy that I cannot stand it. 
2        0     I am not particularly discouraged about the future. 
       1     I feel discouraged about the future. 
       2     I feel I have nothing to look forward to. 
       3     I feel that the future is hopeless and that things cannot improve. 
3        0     I do not feel like a failure. 
       1     I feel I have failed more than the average person. 
       2     As I look back on my life, all I can see is a lot of failure. 
       3     I feel I am a complete failure as a person. 
4 0 I get as much satisfaction out of things as I used to. 
1 I don’t enjoy things the way I used to. 
2 I don’t get any real satisfaction out of anything anymore. 
3     I am dissatisfied or bored with everything. 
5 0 I don’t feel particularly guilty. 
1 I feel guilty a good part of the time. 
2 I feel guilty most of the time. 
3 I feel guilty all of the time. 
6        0     I don’t feel that I am being punished. 
       1     I feel I may be punished. 
       2     I expect to be punished. 
       3     I feel I am being punished. 
7 0 I don’t feel disappointed in myself. 
1 I am disappointed in myself. 
2 I am disgusted with myself. 
3 I hate myself. 
8 0 I don’t feel I am worse than anybody else. 
1 I am critical of myself for my weaknesses or mistakes. 
2 I blame myself all the time for faults. 
3 I blame myself for everything bad that happens. 
9 0 I don’t have any thoughts of killing myself. 
1 I have thoughts of killing myself but I would not carry them out. 
2 I would like to kill myself. 
3 I would kill myself if I had the chance. 
10 0 I don’t cry anymore than usual. 
1 I cry more now than I used to. 
2 I cry all the time now. 
3 I would kill myself if I had the chance. 
11 0 I am not more irritated by things than I ever am. 
1 I am slightly more irritated now than usual. 
2 I am quite annoyed or irritated a good deal of the time. 
3    I feel irritated all the time now. 
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12 0 I have not lost interest in other people. 
1 I am less interested in other people than I used to be. 
2 I have lost most of my interest in other people. 
3 I have lost all my interest in other people. 
13 4 I make decisions about as well as I ever could. 
5 I put off making decisions more than I used to. 
6 I have a greater difficulty in making decisions than before. 
7 I can’t make decisions at all anymore. 
14 0     I don’t feel I look any worse than I used to. 
1 I am worried that I am looking old or unattractive. 
2 I feel that there are permanent changes in my appearance that make me look 
unattractive. 
3     I believe that I look ugly. 
15 0     I can work about as well as before. 
1 It takes an extra effort to get started at doing something. 
2 I have to push myself very hard to do anything. 
3 I can’t do any work at all. 
16 0 I can sleep as well as usual. 
1 I don’t sleep as well as I used to. 
2 I wake up 1-2 hours earlier than usual and find it hard to get back to sleep. 
3 I wake up several hours earlier than I used to and cannot get back to sleep. 
17 0 I don’t get more tired than usual. 
1 I get tired more easily than I used to. 
2 I get tired from doing almost anything. 
3 I am too tired to do anything. 
18 0 My appetite is no worse than usual. 
1 My appetite is not as good as it used to be. 
2 My appetite is much worse now. 
3 I have no appetite at all anymore. 
19 0 I haven’t lost much weight, if any, lately. 
1 I have lost more than five pounds. 
2 I have lost more than ten pounds. 
3 I have lost more than fifteen pounds trying to lose weight. 
Score 0 if you have been purposely trying to lose weight. 
20 0 I am no more worried about my health than usual. 
1 I am worried about my physical problems such as aches and pains or upset 
stomach. 
2 I am very worried about physical problems and it’s hard to think of much else. 
3 I am so worried about my physical problems that I can't think about anything else. 
21 0 I have not noticed any recent change in my interest in sex. 
1 I am less interested in sex. 
2 I am much less interested in sex. 
3 I have lost interest in sex completely. 
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PASS 
 
Individuals who experience pain develop different ways to respond to that pain. We would like to know 
what you do or what you think about when in pain. Please use the rating scale below to indicate how often 
you engage in each of the following thoughts or activities. Circle any number from 0 (“Never”) to 5 
(“Always”) for each item. 
  
 NEVER   ALWAYS 
I think if my pain gets too severe, it will never 
decrease. 0 1 2 3 4 5 
My mind is calm when I am in pain. 0 1 2 3 4 5 
When I feel pain, I try to stay as still as possible. 0 1 2 3 4 5 
I become sweaty when in pain. 0 1 2 3 4 5 
When I feel pain, I am afraid that something terrible 
will happen. 0 1 2 3 4 5 
My thoughts are agitated and keyed up as pain 
approaches. 0 1 2 3 4 5 
I go immediately to bed when I feel severe pain. 0 1 2 3 4 5 
Even though it hurts, I know that I’m going to be 
OK. 0 1 2 3 4 5 
My body gets shaky when I hurt. 0 1 2 3 4 5 
I feel disoriented and confused when I hurt. 0 1 2 3 4 5 
When pain gets severe, I call my doctor or go to the 
emergency room. 0 1 2 3 4 5 
I begin trembling when engaging in an activity that 
increases pain. 0 1 2 3 4 5 
When I feel pain, I become afraid of dying. 0 1 2 3 4 5 
I can’t think straight when in pain. 0 1 2 3 4 5 
I will stop any activity as soon as I sense pain coming 
on. 
0 1 2 3 4 5 
Even if I do an activity that causes pain, I know it 
will decrease later. 0 1 2 3 4 5 
Pain seems to cause my heart to pound or race. 0 1 2 3 4 5 
I think I have a serious medical problem that my 
physician has failed to uncover. 0 1 2 3 4 5 
As soon as pain comes on, I take medication to 
reduce it. 0 1 2 3 4 5 
I have pressure or tightness in my chest when in pain. 0 1 2 3 4 5 
When I feel pain I think that I might be seriously ill. 0 1 2 3 4 5 
During painful episodes it is difficult for me to think 
of anything besides the pain. 0 1 2 3 4 5 
I avoid important activities when I hurt. 0 1 2 3 4 5 
When I sense pain, I feel dizzy or faint. 0 1 2 3 4 5 
Pain sensations are terrifying. 0 1 2 3 4 5 
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When I hurt, I think about the pain constantly. 0 1 2 3 4 5 
I take medication if I know I need to do something 
that usually increases pain. 0 1 2 3 4 5 
I have trouble catching my breath when I have pain 
sensations. 0 1 2 3 4 5 
I dread feeling pain. 0 1 2 3 4 5 
 
I am bothered by unwanted thoughts when I’m in 
pain. 
 
0 
 
1 
 
2 
 
3 
 
4 
 
5 
If a chance comes to do something I enjoy, I do it 
even if it causes pain. 0 1 2 3 4 5 
Pain makes me nauseous. 0 1 2 3 4 5 
When pain comes on strong, I think I might become 
paralyzed or more disabled. 0 1 2 3 4 5 
I find it hard to concentrate when I hurt. 0 1 2 3 4 5 
I seek reassurance that I am OK during times of more 
severe pain. 0 1 2 3 4 5 
I find it difficult to calm my body down after periods 
of pain. 0 1 2 3 4 5 
I worry when I am in pain. 0 1 2 3 4 5 
My stomach bothers me when I experience pain. 0 1 2 3 4 5 
I try to avoid activities that cause pain. 0 1 2 3 4 5 
I can think pretty clearly even while experiencing 
severe pain 0 1 2 3 4 5 
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Pain Self-Efficacy Questionnaire (PSEQ) by M.K. Nicholas (1989) 
Please rate how confident you are that you can do the following things at present despite the pain. To 
indicate your answer circle one of the numbers on the scale under each item, where 0 = not at all 
confident and 6 = completely confident.  
 
Remember, this questionnaire is not asking whether or not you have been doing these things, but rather 
how confident you are that you can do them at present, despite the pain. 
 
I can enjoy things, despite the pain 
0        1         2         3         4         5         6 
        Not at all confident     Completely confident 
 
I can do most of the household chores (e.g., tidying-up, washing dishes, etc), despite the pain. 
0        1         2         3         4         5         6 
 Not at all confident     Completely confident 
 
I can socialize with my friends or family members as often as I used to, despite the pain. 
0        1         2         3         4         5         6 
 Not at all confident     Completely confident 
 
I can cope with my pain in most situations 
0        1         2         3         4         5         6 
 Not at all confident     Completely confident 
 
 
I can do some form of work, despite the pain (“work” = house work, paid and unpaid work). 
0        1         2         3         4         5         6 
 Not at all confident     Completely confident 
 
I can still do many of the things I enjoy doing, such as hobbies or leisure despite the pain 
0        1         2         3         4         5         6 
 Not at all confident     Completely confident 
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I can cope with my pain without medication 
0        1         2         3         4         5         6 
  Not at all confident     Completely confident 
 
I can still accomplish many of my goals in life, despite the pain. 
0        1         2         3         4         5         6 
 Not at all confident     Completely confident 
 
I can live a normal life style, despite the pain 
0        1         2         3         4         5         6 
 Not at all confident     Completely confident 
 
I can gradually become more active, despite the pain 
0        1         2         3         4         5         6 
 Not at all confident     Completely confident 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
102 
 
Sleep Quality Rating Scale 
 
Please rate your quality of sleep on a scale of zero to ten, with 0 representing no problems 
with sleep and 10 representing worst possible sleep  
 
 | | | | | | | | | | | 
 0 1 2 3 4 5 6 7 8 9 10 
           No          Moderate             Worst 
        Problems           Problems            Possible  
        with Sleep          with Sleep             Sleep 
 
 
 
 
 
 
Pain Rating Scale 
 
Please rate your pain on a scale of zero to ten, with zero equals no pain and ten equals the 
worst pain imaginable. 
 
 | | | | | | | | | | | 
 0 1 2 3 4 5 6 7 8 9 10 
           No          Moderate             Worst 
          Pain               Pain           Possible Pain  
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AUTHORIZATION TO RELEASE INFORMATION: 
 
I authorize PRA to release from my medical records any information required by my insurance carrier or 
any government agency for processing my claim. 
   
I understand that reports pertaining to my evaluation and treatment will be made available to the 
insurance carrier which has authorized or may authorize payment for services received.  This may include 
information about mental health treatment and alcohol and drug abuse treatment, HIV/AIDS, genetic 
testing, or information provided by my family.  While this information is important to our evaluation and 
treatment planning, if you do not wish to have such information disclosed, please notify us in writing and 
this information may be redacted from any report that is released for the purposes of treatment, payment 
or business operations, or to a designated recipient for which you have provided written authorization to 
receive information. 
   
I understand that my family may be present at times during my course of treatment for therapeutic reasons 
and that they will be exposed to information regarding my condition and treatment.  
 
PRA routinely conducts program evaluation studies and other research in order to improve the quality of 
services. PRA is authorized to use my health related information, including physical data and 
psychological test results.  PRA will not release my name and address or other personal identifying data 
in the course of its research.  
  
I understand that information cannot be further released without specific written consent, except in 
accordance with state and federal regulations. 
   
This authorization may be revoked at any time, in writing, except to the extent that PRA has already taken 
action in reliance on it. 
 
I understand that it is my right to refuse to sign this authorization and that treatment is not conditioned 
upon this signature. 
 
 
CONFIDENTIALITY 
Maintaining your privacy is an important right that we strive to uphold.  Please see Notice of Privacy 
Practices for specific information as to how we strive to achieve that.  (Date provided__________ 
Initials______) 
 
_____________________________________________  ________________________ 
Client Signature or Person Lawfully Authorized / Relationship   Date 
 
______________________________________________________ 
Print Client Name 
 
______________________________________________________  ____________________________ 
PRA Representative       Date 
 
 
 
